,Start Date,Start Price,End Date,End Price,Weekly Returns,Bin Label,News,Basics
0,2023-01-08,260.24468994140625,2023-01-15,256.9632873535156,-0.01260891274526843,D2,[],{}
1,2023-01-15,256.9632873535156,2023-01-22,248.93460083007812,-0.03124448868212093,D4,[],{}
2,2023-01-22,248.93460083007812,2023-01-29,239.8657684326172,-0.03643058203729299,D4,[],{}
3,2023-01-29,239.8657684326172,2023-02-05,231.8466033935547,-0.033431886056368376,D4,[],{}
4,2023-02-05,231.8466033935547,2023-02-12,229.3217010498047,-0.010890400406099676,D2,[],{}
5,2023-02-12,229.3217010498047,2023-02-19,229.46466064453125,0.0006234019461399676,U1,[],{}
6,2023-02-19,229.46466064453125,2023-02-26,222.91070556640625,-0.028561936551432132,D3,[],{}
7,2023-02-26,222.91070556640625,2023-03-05,224.00779724121094,0.00492166435890562,U1,[],{}
8,2023-03-05,224.00779724121094,2023-03-12,217.3870849609375,-0.02955572244275173,D3,[],{}
9,2023-03-12,217.3870849609375,2023-03-19,219.21875,0.008425822717994746,U1,[],{}
10,2023-03-19,219.21875,2023-03-26,227.0796661376953,0.03585877639433366,U4,[],{}
11,2023-03-26,227.0796661376953,2023-04-02,230.62852478027344,0.015628253744332188,U2,[],"{""assetTurnoverTTM"": 0.3784, ""bookValue"": 5348, ""cashRatio"": 2.2201899402040097, ""currentRatio"": 3.1448, ""ebitPerShare"": 3.7807, ""eps"": 5.2807, ""ev"": 159129.5, ""fcfMargin"": 0.1179, ""fcfPerShareTTM"": 14.103, ""grossMargin"": 0.7245, ""inventoryTurnoverTTM"": 1.3855, ""longtermDebtTotalAsset"": 0.6849, ""longtermDebtTotalCapital"": 0.9077, ""longtermDebtTotalEquity"": 11.3614, ""netDebtToTotalCapital"": 0.4487, ""netDebtToTotalEquity"": 5.6161, ""netMargin"": 0.4654, ""operatingMargin"": 0.3332, ""payoutRatioTTM"": 0.5372, ""pb"": 24.1388, ""peTTM"": 16.306, ""pfcfTTM"": 17.1417, ""pretaxMargin"": 0.5638, ""psTTM"": 4.9292, ""quickRatio"": 2.7923, ""receivablesTurnoverTTM"": 4.8442, ""roaTTM"": 0.1144, ""roeTTM"": 2.0999, ""roicTTM"": 0.1659, ""rotcTTM"": 0.1924, ""salesPerShare"": 11.3476, ""sgaToSale"": 0.2755, ""totalDebtToEquity"": 11.5174, ""totalDebtToTotalAsset"": 0.6943, ""totalDebtToTotalCapital"": 0.9201, ""totalRatio"": 1.0641, ""period"": ""2023-03-31""}"
12,2023-04-02,230.62852478027344,2023-04-09,241.66629028320312,0.04785949835756731,U5,[],"{""assetTurnoverTTM"": 0.3784, ""bookValue"": 5348, ""cashRatio"": 2.2201899402040097, ""currentRatio"": 3.1448, ""ebitPerShare"": 3.7807, ""eps"": 5.2807, ""ev"": 159129.5, ""fcfMargin"": 0.1179, ""fcfPerShareTTM"": 14.103, ""grossMargin"": 0.7245, ""inventoryTurnoverTTM"": 1.3855, ""longtermDebtTotalAsset"": 0.6849, ""longtermDebtTotalCapital"": 0.9077, ""longtermDebtTotalEquity"": 11.3614, ""netDebtToTotalCapital"": 0.4487, ""netDebtToTotalEquity"": 5.6161, ""netMargin"": 0.4654, ""operatingMargin"": 0.3332, ""payoutRatioTTM"": 0.5372, ""pb"": 24.1388, ""peTTM"": 16.306, ""pfcfTTM"": 17.1417, ""pretaxMargin"": 0.5638, ""psTTM"": 4.9292, ""quickRatio"": 2.7923, ""receivablesTurnoverTTM"": 4.8442, ""roaTTM"": 0.1144, ""roeTTM"": 2.0999, ""roicTTM"": 0.1659, ""rotcTTM"": 0.1924, ""salesPerShare"": 11.3476, ""sgaToSale"": 0.2755, ""totalDebtToEquity"": 11.5174, ""totalDebtToTotalAsset"": 0.6943, ""totalDebtToTotalCapital"": 0.9201, ""totalRatio"": 1.0641, ""period"": ""2023-03-31""}"
13,2023-04-09,241.66629028320312,2023-04-16,238.49900817871094,-0.013106015327088105,D2,[],"{""assetTurnoverTTM"": 0.3784, ""bookValue"": 5348, ""cashRatio"": 2.2201899402040097, ""currentRatio"": 3.1448, ""ebitPerShare"": 3.7807, ""eps"": 5.2807, ""ev"": 159129.5, ""fcfMargin"": 0.1179, ""fcfPerShareTTM"": 14.103, ""grossMargin"": 0.7245, ""inventoryTurnoverTTM"": 1.3855, ""longtermDebtTotalAsset"": 0.6849, ""longtermDebtTotalCapital"": 0.9077, ""longtermDebtTotalEquity"": 11.3614, ""netDebtToTotalCapital"": 0.4487, ""netDebtToTotalEquity"": 5.6161, ""netMargin"": 0.4654, ""operatingMargin"": 0.3332, ""payoutRatioTTM"": 0.5372, ""pb"": 24.1388, ""peTTM"": 16.306, ""pfcfTTM"": 17.1417, ""pretaxMargin"": 0.5638, ""psTTM"": 4.9292, ""quickRatio"": 2.7923, ""receivablesTurnoverTTM"": 4.8442, ""roaTTM"": 0.1144, ""roeTTM"": 2.0999, ""roicTTM"": 0.1659, ""rotcTTM"": 0.1924, ""salesPerShare"": 11.3476, ""sgaToSale"": 0.2755, ""totalDebtToEquity"": 11.5174, ""totalDebtToTotalAsset"": 0.6943, ""totalDebtToTotalCapital"": 0.9201, ""totalRatio"": 1.0641, ""period"": ""2023-03-31""}"
14,2023-04-16,238.49900817871094,2023-04-23,232.64146423339844,-0.024560034819613774,D3,[],{}
15,2023-04-23,232.64146423339844,2023-04-30,228.71102905273438,-0.016894817927731176,D2,[],{}
16,2023-04-30,228.71102905273438,2023-05-07,225.648681640625,-0.013389592206343837,D2,[],{}
17,2023-05-07,225.648681640625,2023-05-14,222.23336791992188,-0.01513553589531913,D2,[],{}
18,2023-05-14,222.23336791992188,2023-05-21,215.15281677246094,-0.03186088216064964,D4,[],{}
19,2023-05-21,215.15281677246094,2023-05-28,208.90298461914062,-0.029048339905909493,D3,[],{}
20,2023-05-28,208.90298461914062,2023-06-04,210.0008087158203,0.005255186270704426,U1,[],{}
21,2023-06-04,210.0008087158203,2023-06-11,210.66526794433594,0.0031640793794027733,U1,[],{}
22,2023-06-11,210.66526794433594,2023-06-18,221.16195678710938,0.049826385455940425,U5,[],{}
23,2023-06-18,221.16195678710938,2023-06-25,218.70628356933594,-0.01110350646850744,D2,[],{}
24,2023-06-25,218.70628356933594,2023-07-02,213.80462646484375,-0.022412054306332863,D3,[],"{""assetTurnoverTTM"": 0.3454, ""bookValue"": 6781, ""cashRatio"": 2.0031584488506757, ""currentRatio"": 2.7712, ""ebitPerShare"": 4.9981, ""eps"": 2.568, ""ev"": 146076.7, ""fcfMargin"": 0.5494, ""fcfPerShareTTM"": 18.1028, ""grossMargin"": 0.7405, ""inventoryTurnoverTTM"": 1.4331, ""longtermDebtTotalAsset"": 0.6578, ""longtermDebtTotalCapital"": 0.869, ""longtermDebtTotalEquity"": 8.7564, ""netDebtToTotalCapital"": 0.3995, ""netDebtToTotalEquity"": 4.0254, ""netMargin"": 0.1974, ""operatingMargin"": 0.3842, ""payoutRatioTTM"": 0.5457, ""pb"": 17.5167, ""peTTM"": 14.8867, ""pfcfTTM"": 12.2644, ""pretaxMargin"": 0.231, ""psTTM"": 4.4685, ""quickRatio"": 2.4801, ""receivablesTurnoverTTM"": 4.7651, ""roaTTM"": 0.1037, ""roeTTM"": 1.6415, ""roicTTM"": 0.1449, ""rotcTTM"": 0.1759, ""salesPerShare"": 13.0093, ""sgaToSale"": 0.2595, ""totalDebtToEquity"": 9.0759, ""totalDebtToTotalAsset"": 0.6818, ""totalDebtToTotalCapital"": 0.9008, ""totalRatio"": 1.0812, ""period"": ""2023-06-30""}"
25,2023-07-02,213.80462646484375,2023-07-09,210.559326171875,-0.0151788122952633,D2,[],"{""assetTurnoverTTM"": 0.3454, ""bookValue"": 6781, ""cashRatio"": 2.0031584488506757, ""currentRatio"": 2.7712, ""ebitPerShare"": 4.9981, ""eps"": 2.568, ""ev"": 146076.7, ""fcfMargin"": 0.5494, ""fcfPerShareTTM"": 18.1028, ""grossMargin"": 0.7405, ""inventoryTurnoverTTM"": 1.4331, ""longtermDebtTotalAsset"": 0.6578, ""longtermDebtTotalCapital"": 0.869, ""longtermDebtTotalEquity"": 8.7564, ""netDebtToTotalCapital"": 0.3995, ""netDebtToTotalEquity"": 4.0254, ""netMargin"": 0.1974, ""operatingMargin"": 0.3842, ""payoutRatioTTM"": 0.5457, ""pb"": 17.5167, ""peTTM"": 14.8867, ""pfcfTTM"": 12.2644, ""pretaxMargin"": 0.231, ""psTTM"": 4.4685, ""quickRatio"": 2.4801, ""receivablesTurnoverTTM"": 4.7651, ""roaTTM"": 0.1037, ""roeTTM"": 1.6415, ""roicTTM"": 0.1449, ""rotcTTM"": 0.1759, ""salesPerShare"": 13.0093, ""sgaToSale"": 0.2595, ""totalDebtToEquity"": 9.0759, ""totalDebtToTotalAsset"": 0.6818, ""totalDebtToTotalCapital"": 0.9008, ""totalRatio"": 1.0812, ""period"": ""2023-06-30""}"
26,2023-07-09,210.559326171875,2023-07-16,219.01443481445312,0.04015546970204675,U5,[],"{""assetTurnoverTTM"": 0.3454, ""bookValue"": 6781, ""cashRatio"": 2.0031584488506757, ""currentRatio"": 2.7712, ""ebitPerShare"": 4.9981, ""eps"": 2.568, ""ev"": 146076.7, ""fcfMargin"": 0.5494, ""fcfPerShareTTM"": 18.1028, ""grossMargin"": 0.7405, ""inventoryTurnoverTTM"": 1.4331, ""longtermDebtTotalAsset"": 0.6578, ""longtermDebtTotalCapital"": 0.869, ""longtermDebtTotalEquity"": 8.7564, ""netDebtToTotalCapital"": 0.3995, ""netDebtToTotalEquity"": 4.0254, ""netMargin"": 0.1974, ""operatingMargin"": 0.3842, ""payoutRatioTTM"": 0.5457, ""pb"": 17.5167, ""peTTM"": 14.8867, ""pfcfTTM"": 12.2644, ""pretaxMargin"": 0.231, ""psTTM"": 4.4685, ""quickRatio"": 2.4801, ""receivablesTurnoverTTM"": 4.7651, ""roaTTM"": 0.1037, ""roeTTM"": 1.6415, ""roicTTM"": 0.1449, ""rotcTTM"": 0.1759, ""salesPerShare"": 13.0093, ""sgaToSale"": 0.2595, ""totalDebtToEquity"": 9.0759, ""totalDebtToTotalAsset"": 0.6818, ""totalDebtToTotalCapital"": 0.9008, ""totalRatio"": 1.0812, ""period"": ""2023-06-30""}"
27,2023-07-16,219.01443481445312,2023-07-23,226.13101196289062,0.03249364433201207,U4,[],{}
28,2023-07-23,226.13101196289062,2023-07-30,227.62364196777344,0.006600731106831903,U1,[],{}
29,2023-07-30,227.62364196777344,2023-08-06,234.2779541015625,0.029233835625612103,U3,[],{}
30,2023-08-06,234.2779541015625,2023-08-13,252.79640197753906,0.0790447737474631,U5+,[],{}
31,2023-08-13,252.79640197753906,2023-08-20,254.1747589111328,0.0054524388907886134,U1,[],{}
32,2023-08-20,254.1747589111328,2023-08-27,248.8936004638672,-0.020777666790714133,D3,[],{}
33,2023-08-27,248.8936004638672,2023-09-03,249.21395874023438,0.0012871294230552,U1,[],{}
34,2023-09-03,249.21395874023438,2023-09-10,251.85455322265625,0.0105956925357229,U2,[],{}
35,2023-09-10,251.85455322265625,2023-09-17,253.1068878173828,0.00497245167380167,U1,[],{}
36,2023-09-17,253.1068878173828,2023-09-24,259.883056640625,0.02677196532135162,U3,"[{""date"": ""20230923233210"", ""headline"": ""Patience Is The Name Of This (Market) Game"", ""summary"": ""Market weakness continues due to concerns about the Fed and interest rates. Read why market weakness during earnings quiet periods may present buying opportunities.""}, {""date"": ""20230924000500"", ""headline"": ""The Hedge Fund That Made a Killing Betting Against Lina Khan"", ""summary"": ""The efforts by Federal Trade Commission Chair Lina Khan to protect Main Street are inadvertently enriching some on Wall Street, generating outsize profits for Pentwater Capital Management and other large hedge funds that bet on merger deals.  In both cases, the FTC\u2019s intervention spooked investors and sent shares of the target companies swinging.""}, {""date"": ""20230924080600"", ""headline"": ""GLP-1 drugs may already be impacting aesthetics sectors, survey finds"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230924193331"", ""headline"": ""Kyowa Kirin: High-Risk High-Return Call Reiterating Our Buy Rating"", ""summary"": ""Kyowa Kirin's recent track record for new drug trial success has been poor, but the partnership with Amgen provides reassurance. Read why KYKOF stock is a Buy.""}]",{}
37,2023-09-24,259.883056640625,2023-10-01,260.9121398925781,0.003959793551975066,U1,"[{""date"": ""20230923233210"", ""headline"": ""Patience Is The Name Of This (Market) Game"", ""summary"": ""Market weakness continues due to concerns about the Fed and interest rates. Read why market weakness during earnings quiet periods may present buying opportunities.""}, {""date"": ""20230924000500"", ""headline"": ""The Hedge Fund That Made a Killing Betting Against Lina Khan"", ""summary"": ""The efforts by Federal Trade Commission Chair Lina Khan to protect Main Street are inadvertently enriching some on Wall Street, generating outsize profits for Pentwater Capital Management and other large hedge funds that bet on merger deals.  In both cases, the FTC\u2019s intervention spooked investors and sent shares of the target companies swinging.""}, {""date"": ""20230924080600"", ""headline"": ""GLP-1 drugs may already be impacting aesthetics sectors, survey finds"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230924193331"", ""headline"": ""Kyowa Kirin: High-Risk High-Return Call Reiterating Our Buy Rating"", ""summary"": ""Kyowa Kirin's recent track record for new drug trial success has been poor, but the partnership with Amgen provides reassurance. Read why KYKOF stock is a Buy.""}, {""date"": ""20230924224000"", ""headline"": ""FDA Strikes Off Coherus BioSciences' New Injector Biosimilar Treatment For Cancer Patients"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230925020100"", ""headline"": ""Analysts\u2019 Top Healthcare Picks: Cytokinetics (CYTK), Amgen (AMGN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230925075000"", ""headline"": ""Beat the Market Like Zacks: Elementis, Novo Nordisk, Amgen in Focus"", ""summary"": ""Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.""}, {""date"": ""20230925090007"", ""headline"": ""Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It"", ""summary"": ""Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.""}, {""date"": ""20230925123800"", ""headline"": ""Amgen Inc. stock falls Monday, underperforms market"", ""summary"": ""Shares of Amgen Inc. shed 0.31% to $266.86 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20230925130206"", ""headline"": ""Dow Jones Biotech Giant Amgen, Meta Stock, Eye Buy Points In Stock Market Correction"", ""summary"": ""Dow Jones biotech leader Amgen and Meta stock are among the best stocks to watch in today's stock market action.""}, {""date"": ""20230926043800"", ""headline"": ""Wall Street analysts expect the S&P 500 to rise 19% over the next 12 months. Here are their 10 favorite stocks."", ""summary"": ""Outside of a handful of highflying technology stocks, U.S. stocks have been practically flat in 2023, but on Wall Street, some analysts remain as bullish as...""}, {""date"": ""20230926081800"", ""headline"": ""Akebia gains as Australia clears kidney disease therapy"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230926082020"", ""headline"": ""Big Pharma R&D Spending: The Secret Ingredient To Outperformance?"", ""summary"": ""High R&D spending by pharma companies does not necessarily lead to sales growth, let alone shareholder returns. See why bold M&A deals may be a different story.""}, {""date"": ""20230926123800"", ""headline"": ""Amgen Inc. stock rises Tuesday, outperforms market"", ""summary"": ""Shares of Amgen Inc. inched 0.82% higher to $269.04 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500...""}, {""date"": ""20230926210800"", ""headline"": ""Are We in a New Golden Age of Merger Arbitrage?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230927043600"", ""headline"": ""Amgen discloses more than $400 million stake in recent IPO Neumora Therapeutics"", ""summary"": ""An Amgen disclosure of a large stake in Neumora Therapeutics indicated the value of its investment in the biotech, which recently went public, has tripled.""}, {""date"": ""20230927060000"", ""headline"": ""Amgen Could Get a Piece of the Obesity Market"", ""summary"": ""Amgen has a couple of shots on goal to break into one of the biggest markets the pharmaceutical industry has ever seen.""}, {""date"": ""20230927071000"", ""headline"": ""September's Shakeout: S&P 500, Nasdaq 100 See Just 13% Of Stocks Above 50-Day Average"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230927123700"", ""headline"": ""Amgen Inc. stock falls Wednesday, underperforms market"", ""summary"": ""Shares of Amgen Inc. shed 0.02% to $268.98 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20230927180020"", ""headline"": ""Amgen (AMGN) Stock Sinks As Market Gains: What You Should Know"", ""summary"": ""In the latest trading session, Amgen (AMGN) closed at $268.98, marking a -0.02% move from the previous day.""}, {""date"": ""20230927211400"", ""headline"": ""FDA Oncologic Drugs Advisory Committee holds virtual meeting"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230927232300"", ""headline"": ""Mirati stock climbs 10% ahead of data presentation, FDA meeting on rival drug"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230927233300"", ""headline"": ""Teva names Novartis exec to lead US commercial business"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230928050000"", ""headline"": ""Earn Double-Digit Income With Options (October 2023)"", ""summary"": ""Earning a decent income from investments higher than the inflation rate is challenging. Check out how we formulate a sustainable and repeatable options income strategy.""}, {""date"": ""20230928084504"", ""headline"": ""3 Biotech Stocks to Watch Ahead of Potential Obesity Drug Approvals"", ""summary"": ""The companies that already have obesity drugs can\u2019t keep up with the demand for their treatments, and the demand for the drugs is only likely to become more intense. That\u2019s because over 42% of the U.S. population was obese as of 2020, while the pervasive publicity around these drugs will make them more popular, and the social and political pressure for insurers to cover the treatments will become more intense. This has led to the rise of biotech stocks to buy. More specifically on the last point""}, {""date"": ""20230928085500"", ""headline"": ""DBS Remains a Buy on Amgen (AMGN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230928110015"", ""headline"": ""The Anti-obesity Drug Market Is About to Get More Crowded"", ""summary"": ""Obesity is an epidemic that affects more than 40% of all American adults, and it's creating a feeding frenzy for investors. With the rise of...""}, {""date"": ""20230928123700"", ""headline"": ""Amgen Inc. stock rises Thursday, outperforms market"", ""summary"": ""Shares of Amgen Inc. inched 0.68% higher to $270.82 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P...""}, {""date"": ""20230928175017"", ""headline"": ""Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know"", ""summary"": ""In the latest trading session, Amgen (AMGN) closed at $270.82, marking a +0.68% move from the previous day.""}, {""date"": ""20230928210900"", ""headline"": ""Check Out What Whales Are Doing With AMGN"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230928220400"", ""headline"": ""Catalyst Watch: Tesla deliveries, Google event, Kellogg spinoff, Amgen drama and Ether ETFs"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230929021200"", ""headline"": ""GLP-1 drug developer Carmot Therapeutics reportedly mulling IPO or buyout"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230929052100"", ""headline"": ""As Merck, AstraZeneca and other drugmakers sign on, Medicare price negotiations face critical moment"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230929062000"", ""headline"": ""As Merck, AstraZeneca and other drugmakers sign on, Medicare price negotiations face critical moment\u00a0"", ""summary"": ""A deadline looms to sign drug-price negotiation agreements as industry watches for legal reprieve.""}, {""date"": ""20230929075100"", ""headline"": ""AskSlim Market Week - Friday, Sep. 29"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230929093400"", ""headline"": ""Amgen Stock Was a Winner in the Third Quarter. These Solar Shares Weren\u2019t."", ""summary"": ""Amgen was the best-performing stock in the Dow Jones Industrial Average in the third quarter, while Zions Bancorp, up 30%, was the top stock in the S&P 500.""}, {""date"": ""20230929123800"", ""headline"": ""Amgen Inc. stock falls Friday, underperforms market"", ""summary"": ""Shares of Amgen Inc. dropped 0.76% to $268.76 Friday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20230929133400"", ""headline"": ""Amgen Stock Was a Winner in the Third Quarter. These Solar Shares Were Not."", ""summary"": ""Amgen was the best-performing stock in both the Dow Jones Industrial Average and Nasdaq 100 in the third quarter, while Zions Bancorp, up 32%, was the top stock in the S&P 500.""}]","{""assetTurnoverTTM"": 0.3207, ""bookValue"": 7656, ""cashRatio"": 2.0491329479768785, ""currentRatio"": 2.8593, ""ebitPerShare"": 3.8848, ""eps"": 3.2156, ""ev"": 168202.84, ""fcfMargin"": 0.3639, ""fcfPerShareTTM"": 17.5308, ""grossMargin"": 0.7385, ""inventoryTurnoverTTM"": 1.4407, ""longtermDebtTotalAsset"": 0.6521, ""longtermDebtTotalCapital"": 0.8667, ""longtermDebtTotalEquity"": 7.7116, ""netDebtToTotalCapital"": 0.3776, ""netDebtToTotalEquity"": 3.3604, ""netMargin"": 0.2506, ""operatingMargin"": 0.3028, ""payoutRatioTTM"": 0.589, ""pb"": 18.6097, ""peTTM"": 18.8311, ""pfcfTTM"": 15.1909, ""pretaxMargin"": 0.2821, ""psTTM"": 5.3097, ""quickRatio"": 2.5629, ""receivablesTurnoverTTM"": 4.6784, ""roaTTM"": 0.0904, ""roeTTM"": 1.2908, ""roicTTM"": 0.123, ""rotcTTM"": 0.147, ""salesPerShare"": 12.8309, ""sgaToSale"": 0.2615, ""totalDebtToEquity"": 7.8981, ""totalDebtToTotalAsset"": 0.6679, ""totalDebtToTotalCapital"": 0.8876, ""totalRatio"": 1.0924, ""period"": ""2023-09-30""}"
38,2023-10-01,260.9121398925781,2023-10-08,259.6597900390625,-0.00479989108222878,D1,"[{""date"": ""20231001220100"", ""headline"": ""Drugmakers comply with Medicare pricing talks despite lawsuits"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231001234500"", ""headline"": ""Horizon Therapeutics ticks higher amid Nasdaq delisting notice for sale to Amgen"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231002065500"", ""headline"": ""Amgen price target raised to $230 from $210 at Barclays"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231002123800"", ""headline"": ""Amgen Inc. stock underperforms Monday when compared to competitors"", ""summary"": ""Shares of Amgen Inc. slid 0.91% to $266.31 Monday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20231002124952"", ""headline"": ""Drugmakers sign on to negotiate Medicare prices under protest"", ""summary"": ""All the drugmakers that make the 10 prescription medicines  subject to the first-ever price negotiations for the U.S. Medicare health program, including Amgen and Novartis, said they signed on to participate in the talks by the Oct. 1 deadline.  The penalties for not doing so would have been steep: drugmakers would have to pay 65% to 95% taxes on their drug's Medicare sales or withdraw all of their products from the Medicare and Medicaid programs, which together provide health benefits to 158 million Americans.  \""Merck will sign the initial agreement with CMS under protest,\"" the U.S. company said in a statement.""}, {""date"": ""20231002223500"", ""headline"": ""Is Amgen's Lung Cancer Drug Lumakras Up to the Mark? FDA Briefing Raises Concerns"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231002234200"", ""headline"": ""Jones Research sees Amgen FDA issues reading through to Mirati"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231003010000"", ""headline"": ""Dive Into Dividends: 14 Must-Have Stocks When Markets Dip"", ""summary"": ""Investors want income-producing investments amid rising interest and costs. Click here to learn about 14 Dividend Stocks with yield and strong dividend growth rates.""}, {""date"": ""20231003043600"", ""headline"": ""FDA staff voice concerns about whether Amgen's CodeBreaK 200 trial 'adequate'"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231003074400"", ""headline"": ""Bad news for Amgen could be 'good' for Mirati Therapeutics, says Stifel"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231003080000"", ""headline"": ""Drugmakers agree to US government price talks amid pushback"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231003080700"", ""headline"": ""Amgen stock dips after FDA reveals concerns about Lumakras study"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231003083900"", ""headline"": ""Drugmakers Agree To Participate For Medicare Drug Price Negotiation With Biden Administration"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231003094830"", ""headline"": ""UPDATE 3-Amgen's late-stage data for lung cancer drug 'not adequate' - FDA staff"", ""summary"": ""The U.S. Food and Drug Administration staff reviewers said on Tuesday Amgen's late-stage study might not be sufficient to confirm the effectiveness for its lung cancer drug, as the firm pursues a traditional nod for the treatment.  Lumakras, which bought in sales of $285 million last year, targets a mutated form of a gene known as KRAS that occurs in about 13% of non-small cell lung cancers - the most common form of the disease.  Amgen's drug was granted accelerated approval by the U.S. FDA in 2021 for advanced lung cancer patients with KRAS mutations whose disease has worsened after treatment with chemotherapy or other medicines.""}, {""date"": ""20231003100806"", ""headline"": ""The 10 pharma companies participating in Medicare price negotiations"", ""summary"": ""Ten pharmaceutical manufacturers are signing the Inflation Reduction Act's Medicare drug price negotiation program. These companies are Bristol Myers Squibb (BMY), AstraZeneca (AZN), Boehringer Ingelheim, Immunex, Janssen Pharmaceuticals, Pharmacyclics, Merck & Company (MRK), Janssen Biotech, Novartis (NVS), and Novo Nordisk (NVO), according to the Biden administration. Yahoo Finance Health Care Reporter Anjalee Khemlani discusses the news. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.""}, {""date"": ""20231003121614"", ""headline"": ""October Dogs Of The Dow: 3 Buyable, 7 Watchable"", ""summary"": ""Discover how the Dow Jones adds and selects stocks, the highest-yielding stocks in October, and the leading performers in the Dow Industrial Index. Click for more.""}, {""date"": ""20231003123800"", ""headline"": ""Amgen Inc. stock falls Tuesday, underperforms market"", ""summary"": ""Shares of Amgen Inc. slipped 1.99% to $261.01 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20231003222700"", ""headline"": ""Dow rallies nearly 100 points on gains in shares of Microsoft, Amgen"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231003233900"", ""headline"": ""Amgen Inc. stock outperforms market on strong trading day"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231004021100"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and Intellia Therapeutics (NTLA)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231004050011"", ""headline"": ""Gilead Sciences: A Healthy Buy With Solid Dividend"", ""summary"": ""Gilead Sciences has outperformed the S&P 500 with a 19% total return since my last Buy rating in August last year. Learn why GILD stock is a buy.""}, {""date"": ""20231004051000"", ""headline"": ""Should You Still Buy the Dow Jones' Best-Performing September Stocks?"", ""summary"": ""A handful of blue-chip tickers defied the bigger bearish tide last month, but that doesn't necessarily make these stocks a buy.""}, {""date"": ""20231004110000"", ""headline"": ""Large-scale proteomics in population-based studies from UK and Iceland"", ""summary"": ""In a paper released today, deCODE Genetics' scientists shared their findings from a plasma proteomics study performed using affinity-based methods. They analyzed the proteins in the context of diseases and diversity in the sequence of the genome and compared measurements made using two platforms of thousands of proteins in samples from large groups from the UK Biobank and Iceland.""}, {""date"": ""20231004155500"", ""headline"": ""Top Research Reports for Amgen, ServiceNow & RTX"", ""summary"": ""Today's Research Daily features new research reports on 16 major stocks, including Amgen Inc. (AMGN), ServiceNow, Inc. (NOW) and RTX Corporation (RTX).""}, {""date"": ""20231004180019"", ""headline"": ""Amgen (AMGN) Surpasses Market Returns: Some Facts Worth Knowing"", ""summary"": ""Amgen (AMGN) reachead $265.44 at the closing of the latest trading day, reflecting a +1.7% change compared to its last close.""}, {""date"": ""20231004190011"", ""headline"": ""Pharma Giants Combine Forces to Fight New M&A Rules"", ""summary"": ""Meet the anti-antitrust coalition. With a looming overhaul of US merger-and-acquisition law set to reshape the economics of the M&A-heavy...""}, {""date"": ""20231004221800"", ""headline"": ""FDA panel finds results from key Amgen Lumakras study unreliable"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231004224100"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA), Veralto Corporation (VLTO) and Amgen (AMGN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231004233900"", ""headline"": ""Amgen Inc. stock underperforms Thursday when compared to competitors"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231005024600"", ""headline"": ""Horizon Therapeutics announces acquisition by Amgen approved in Ireland"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231005025000"", ""headline"": ""Amgen wins Irish approval for planned Horizon Therapeutics purchase"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231005035500"", ""headline"": ""FDA Oncologic Drugs Advisory Committee holds virtual meeting"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231005045100"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Regeneron (REGN) and Alnylam Pharma (ALNY)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231005071600"", ""headline"": ""The Zacks Analyst Blog Highlights Amgen, ServiceNow, RTX, Automatic Data Processing and Canadian Pacific Kansas City"", ""summary"": ""Amgen, ServiceNow, RTX, Automatic Data Processing and Canadian Pacific Kansas City are included in this Analyst Blog.""}, {""date"": ""20231005075300"", ""headline"": ""Mirati stock up 9% amid FDA meeting on rival Amgen drug"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231005145708"", ""headline"": ""UPDATE 2-US FDA panel says Amgen lung cancer drug data cannot be relied on"", ""summary"": ""Advisers to the U.S. Food and Drug Administration on Thursday found that data from a late-stage trial of Amgen's Lumakras could not be relied on, raising questions about the agency's upcoming decision on whether to grant traditional approval of the drug for a type of advanced lung cancer.  The drug was approved by the FDA in 2021 under an accelerated pathway, with confirmatory data a condition for gaining traditional approval.  The main goal of the confirmatory study was progression-free survival (PFS), or how long before the disease begins to worsen, but the FDA questioned some methods used in conducting the trial.""}, {""date"": ""20231005213800"", ""headline"": ""Biotech Sector: On The Verge Of Triumph Or Turmoil?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231005222800"", ""headline"": ""Here\u2019s Why Mirati Therapeutics Stock (NASDAQ:MRTX) Soared Yesterday"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231005233000"", ""headline"": ""Confirmatory Trial Trouble In KRAS"", ""summary"": ""I wrote last year about KRAS-targeting drugs as cancer therapies, and that pretty much means G12C-KRAS targeting ones.""}, {""date"": ""20231005233900"", ""headline"": ""Amgen Inc. stock rises Friday, still underperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231006022200"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Immunic (IMUX), Amgen (AMGN) and Neurocrine (NBIX)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231006025200"", ""headline"": ""Mirati Therapeutics price target raised to $72 from $31 at BMO Capital"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231006030800"", ""headline"": ""Negative Amgen AdCom a positive for Mirati, says Jefferies"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231006033300"", ""headline"": ""Amgen completes acquisition of Horizon Therapeutics"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231006040100"", ""headline"": ""FDA Adcomm Gives Thumbs Down To Amgen's Lumakras For Advanced Form Of Lung Cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231006041100"", ""headline"": ""Analysts Are Bullish on These Healthcare Stocks: United Therapeutics (UTHR), Amgen (AMGN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231006041200"", ""headline"": ""Amgen completes $27.8B acquisition of Horizon Therapeutics"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231006043600"", ""headline"": ""Amgen to continue to seek full approval of Lumakras cancer drug after FDA panel criticizes trial"", ""summary"": ""Amgen will continue to seek full approval for its Lumakras cancer drug as a treatment for a form of lung cancer.""}, {""date"": ""20231006052300"", ""headline"": ""Amgen completes USD28 billion acquisition of Horizon Therapeutics"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231006072400"", ""headline"": ""FDA AdCom Gives Thumbs Down To Late-Stage Data For Amgen's Lumakras In Advanced Form Of Lung Cancer (UPDATED)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231006074700"", ""headline"": ""Amgen's Adcomm Meeting Paves Way To Launch Boost For Mirati Therapeutics' Lung Cancer Drug: Analysts"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231006083000"", ""headline"": ""AMGEN COMPLETES ACQUISITION OF HORIZON THERAPEUTICS PLC"", ""summary"": ""Amgen (NASDAQ: AMGN) today announced that it has completed its acquisition of Horizon Therapeutics plc for $116.50 per share in cash, representing a transaction equity value of approximately $27.8 billion.""}, {""date"": ""20231006090006"", ""headline"": ""Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know"", ""summary"": ""Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.""}, {""date"": ""20231006091100"", ""headline"": ""UPDATE 2-Amgen completes $27.8 bln Horizon Therapeutics deal"", ""summary"": ""Amgen said on Friday it had completed the $27.8 billion acquisition of Horizon Therapeutics after it received the go-ahead from the U.S. Federal Trade Commission (FTC) last month on certain conditions.  Under the settlement terms with the FTC following its lawsuit to block the deal, Amgen is prevented from using anti-competitive tactics to extend the market dominance of Horizon's fast-growing thyroid eye disease treatment Tepezza and gout drug Krystexxa.  The FTC's antitrust lawsuit had raised concerns over increased oversight on mergers and acquisitions in a sector that often turns to consolidation to power future growth as patents on older treatments expire.""}, {""date"": ""20231006091816"", ""headline"": ""Amgen completes $27.8 billion Horizon Therapeutics deal"", ""summary"": ""Under the settlement terms with the FTC following its lawsuit to block the deal, Amgen is prevented from using anti-competitive tactics to extend the market dominance of Horizon's fast-growing thyroid eye disease treatment Tepezza and gout drug Krystexxa.  The FTC's antitrust lawsuit had raised concerns over increased oversight on mergers and acquisitions in a sector that often turns to consolidation to power future growth as patents on older treatments expire.  The deal closure was within the fourth-quarter timeline set by the two companies, and is expected to add to Amgen's adjusted earnings from next year.""}, {""date"": ""20231006113400"", ""headline"": ""Mirati (MRTX) Surges 45% as Sanofi Reportedly Eyes Buyout"", ""summary"": ""A Bloomberg article suggests that pharma giant Sanofi (SNY) is exploring a potential acquisition deal for small cancer drugmaker Mirati Therapeutics (MRTX).""}, {""date"": ""20231006140647"", ""headline"": ""Hedge Funds Won Big on Bets Amgen-Horizon Deal Would Go Through"", ""summary"": ""(Bloomberg) -- Hedge funds Pentwater Capital Management, HBK Investments and Farallon Capital Management are reaping a windfall from bets that US regulators wouldn\u2019t be able to stop Amgen Inc. from completing its $28 billion takeover of Horizon Therapeutics Plc. Most Read from BloombergThe 5% Bond Market Means Pain Is Heading Everyone\u2019s WayThe Moral Case for No Longer Engaging With Elon Musk\u2019s XFake Mansions and Rent-Stabilized Units Emerge in Trump TrialCorporate America Is Ignoring Jay Powell""}, {""date"": ""20231006140948"", ""headline"": ""Biotech-Pharma Trade: Buying Opportunities On The Horizon"", ""summary"": ""Concerns over interest rates, pricing erosion, and Medicare's drug price negotiation plan weigh on biotech and pharma sectors. Learn what investors need to know.""}, {""date"": ""20231006175021"", ""headline"": ""Amgen (AMGN) Increases Yet Falls Behind Market: What Investors Need to Know"", ""summary"": ""Amgen (AMGN) closed at $267.47 in the latest trading session, marking a +0.9% move from the prior day.""}, {""date"": ""20231007222300"", ""headline"": ""As FDA mulls fate of Amgen drug, Sanofi could snap up rival Mirati"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231008075801"", ""headline"": ""SCHD: A Magnificent Buy At This Time"", ""summary"": ""The Schwab U.S. Dividend Equity ETF holds well-diversified, high-quality stocks with economies of scale. Explore more details here.""}]","{""assetTurnoverTTM"": 0.3207, ""bookValue"": 7656, ""cashRatio"": 2.0491329479768785, ""currentRatio"": 2.8593, ""ebitPerShare"": 3.8848, ""eps"": 3.2156, ""ev"": 168202.84, ""fcfMargin"": 0.3639, ""fcfPerShareTTM"": 17.5308, ""grossMargin"": 0.7385, ""inventoryTurnoverTTM"": 1.4407, ""longtermDebtTotalAsset"": 0.6521, ""longtermDebtTotalCapital"": 0.8667, ""longtermDebtTotalEquity"": 7.7116, ""netDebtToTotalCapital"": 0.3776, ""netDebtToTotalEquity"": 3.3604, ""netMargin"": 0.2506, ""operatingMargin"": 0.3028, ""payoutRatioTTM"": 0.589, ""pb"": 18.6097, ""peTTM"": 18.8311, ""pfcfTTM"": 15.1909, ""pretaxMargin"": 0.2821, ""psTTM"": 5.3097, ""quickRatio"": 2.5629, ""receivablesTurnoverTTM"": 4.6784, ""roaTTM"": 0.0904, ""roeTTM"": 1.2908, ""roicTTM"": 0.123, ""rotcTTM"": 0.147, ""salesPerShare"": 12.8309, ""sgaToSale"": 0.2615, ""totalDebtToEquity"": 7.8981, ""totalDebtToTotalAsset"": 0.6679, ""totalDebtToTotalCapital"": 0.8876, ""totalRatio"": 1.0924, ""period"": ""2023-09-30""}"
39,2023-10-08,259.6597900390625,2023-10-15,275.80419921875,0.06217523774959055,U5+,"[{""date"": ""20231007222300"", ""headline"": ""As FDA mulls fate of Amgen drug, Sanofi could snap up rival Mirati"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231008075801"", ""headline"": ""SCHD: A Magnificent Buy At This Time"", ""summary"": ""The Schwab U.S. Dividend Equity ETF holds well-diversified, high-quality stocks with economies of scale. Explore more details here.""}, {""date"": ""20231009020315"", ""headline"": ""14 Best Cancer Stocks To Buy Now"", ""summary"": ""In this article, we discuss 14 best cancer stocks to buy. If you want to skip our detailed discussion on the oncology industry, head directly to 5 Best Cancer Stocks To Buy Now. The global oncology landscape continues to evolve, with ongoing efforts to discover, develop, and provide innovative treatments aimed at improving outcomes for [\u2026]""}, {""date"": ""20231009021500"", ""headline"": ""GCOW: An ETF for Dividend and Free Cash Flow Lovers"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231009025202"", ""headline"": ""TPHD: A Dividend ETF With Biblical Aspirations"", ""summary"": ""Timothy Plan High Dividend Stock ETF holds mostly mid-cap stocks with industrials, utilities, and energy appearing as top sectors. Find out why TPHD is a Buy.""}, {""date"": ""20231009070600"", ""headline"": ""$100 Invested In This Stock 15 Years Ago Would Be Worth $500 Today"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231009081300"", ""headline"": ""Will more bidders emerge or CVR ever be paid in Mirati takeover deal?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231009094900"", ""headline"": ""Coherus (CHRS) Stock Rises on BLA Re-Filing for Udenyca Onbody"", ""summary"": ""Coherus (CHRS) resubmits biologics license application for Udenyca Onbody, an on-body injector presentation of Udenyca to the FDA. Stock rises.""}, {""date"": ""20231009100100"", ""headline"": ""Mirati (MRTX) Gets Buyout Offer From Bristol Myers for $4.8B"", ""summary"": ""Sanofi (SNY) is set to acquire Mirati (MRTX) for $58 per share in cash along with a contingent value right of $12 per share, tied to a regulatory milestone.""}, {""date"": ""20231009101500"", ""headline"": ""2 Magnificent Dividend Stocks to Buy Hand Over Fist in October"", ""summary"": ""Investing in stocks may not look particularly appealing at the moment, given that the 10-year U.S. Treasury bond is offering a near 5% annualized yield.  The drugmaker also sports a moderate cash payout ratio of 42%, implying that it can comfortably support additional increases to the dividend in the years ahead.""}, {""date"": ""20231009204113"", ""headline"": ""Oppenheimer Maintains AMGEN (AMGN) Outperform Recommendation"", ""summary"": """"}, {""date"": ""20231010020700"", ""headline"": ""Neumora Therapeutics appoints Lenz as EVP, Head of Research, Development"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231010050000"", ""headline"": ""SCHD: Still My Favorite Stagflation Hedge"", ""summary"": ""Schwab U.S. Dividend Equity ETF is an excellent hedge against possible stagflation due to its focus on dividends. Read why SCHD ETF is my stagflation hedge.""}, {""date"": ""20231010051400"", ""headline"": ""Video: Dow Movers: AMGN, KO"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231010065300"", ""headline"": ""Should You Still Buy the Nasdaq's Best-Performing September Stocks?"", ""summary"": ""Stocks pulled back in September, primarily due to the Federal Reserve forecast that rates would stay higher for longer.  Unsurprisingly, the Nasdaq Composite took the news worse than the other two major indexes, as shown in the chart below.  Let's take a look at the three top performers on the Nasdaq to see whether any are worth buying.""}, {""date"": ""20231010082738"", ""headline"": ""High Yield Stock Watchlist - October 2023"", ""summary"": ""The majority of the stocks on my watchlist are undervalued based on dividend yield theory. Read more here.""}, {""date"": ""20231010113614"", ""headline"": ""Amgen (AMGN) Valuation: A Comprehensive Analysis of Its Market Value"", ""summary"": ""A deep dive into the intrinsic value and financial performance of Amgen Inc (AMGN)""}, {""date"": ""20231010123800"", ""headline"": ""Amgen Inc. stock falls Tuesday, underperforms market"", ""summary"": ""Shares of Amgen Inc. slipped 0.11% to $271.25 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20231010232900"", ""headline"": ""What You Missed On Wall Street on Wednesday"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231011004500"", ""headline"": ""These Stocks Are Moving the Most Today: Exxon, Pioneer Natural, Silk Road Medical, DaVita, Amgen, Lilly, and More"", ""summary"": ""Exxon Mobil to purchase shale-drilling company Pioneer Natural Resources for $59.5 billion in stock, Silk Road Medical reduces full-year revenue guidance,...""}, {""date"": ""20231011013500"", ""headline"": ""Amgen upgraded to Outperform from Market Perform at Leerink"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231011014600"", ""headline"": ""Analysts Conflicted on These Healthcare Names: Baxter International (BAX), Amgen (AMGN) and Alnylam Pharma (ALNY)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231011015000"", ""headline"": ""Amgen resumed with a Neutral at BofA"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231011021100"", ""headline"": ""Axsome Therapeutics appoints Mahony to board of directors"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231011034800"", ""headline"": ""Amgen\u2019s cancer-drug pipeline looks promising despite FDA setback, analysts say"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231011044700"", ""headline"": ""Amgen's cancer-drug pipeline looks promising despite FDA setback, analysts say "", ""summary"": ""Strong oncology, obesity, and cardiovascular drug candidates behind rating upgrade""}, {""date"": ""20231011052500"", ""headline"": ""Amgen gains as Leerink upgrades on earnings upside and catalysts"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231011070500"", ""headline"": ""What You Missed On Wall Street This Morning"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231011070500"", ""headline"": ""Expert Ratings for Amgen"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231011073940"", ""headline"": ""Amgen's Acquisition Of Horizon Means The Stock Is A Buy"", ""summary"": ""Amgen strengthens its inflammation portfolio and expands globally with the $27.8 billion acquisition of Horizon. Find out if AMGN stock is a buy.""}, {""date"": ""20231011084000"", ""headline"": ""10 Health Care Stocks Whale Activity In Today's Session"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231011093738"", ""headline"": ""Amgen upgraded, Texas Instruments downgraded: Wall Street's top analyst calls"", ""summary"": ""Today's top research calls for upgrade, downgrade and initiate on stocks, as compiled by The Fly.""}, {""date"": ""20231011123800"", ""headline"": ""Amgen Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Amgen Inc. advanced 4.55% to $283.60 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...""}, {""date"": ""20231011130656"", ""headline"": ""Markets Rise at Midday as Bond Yields Fall Ahead of Fed Meeting Minutes"", ""summary"": ""U.S. equites rose at midday on Wednesday, Oct. 11, 2023, as bond yields extended their decline and ahead of the release of minutes from the latest Fed meeting.""}, {""date"": ""20231011132700"", ""headline"": ""Exxon\u2019s Deal for Pioneer Is No Big Payday for Arbitragers"", ""summary"": ""The arbitrage spread appears to be about 2.5% in the transaction but pros say they can enhance the return with dividends""}, {""date"": ""20231011155252"", ""headline"": ""Dow Jones Rises After Fed Minutes As House Vote On New Speaker Looms; Meta Breaks Out"", ""summary"": ""Dow Jones rose after the Fed meeting minutes for September were released and the House planned to vote on a new speaker. Meta broke out.""}, {""date"": ""20231011160856"", ""headline"": ""Amgen Stock Surges To 10-Month High, Up 5% On An Unexpected Upgrade"", ""summary"": ""Amgen stock snagged an upgrade Wednesday and surged to a 10-month high as one analyst examined the biotech behemoth's post-Horizon future.""}, {""date"": ""20231011162756"", ""headline"": ""Plug Power, ChargePoint, Amgen: Top Stocks"", ""summary"": ""Plug Power (PLUG) shares close Wednesday higher after raising its forward revenue outlook through 2027. EV infrastructure company ChargePoint's (CHPT) stock tumbles while raising $232 million in its path to profitability. Lastly, Leerink Partners upgrade Amgen (AMGN) to \""Outperform.\"" Yahoo Finance's Julie Hyman and Josh Lipton monitor several of the day's top trending stocks in the after-hours trading session. For more expert insight and the latest market action,\u00a0click here\u00a0to watch this full episode of Yahoo Finance Live.""}, {""date"": ""20231011163303"", ""headline"": ""B of A Securities Reiterates AMGEN (AMGN) Neutral Recommendation"", ""summary"": """"}, {""date"": ""20231011163303"", ""headline"": ""Leerink Partners Upgrades AMGEN (AMGN)"", ""summary"": """"}, {""date"": ""20231012012700"", ""headline"": ""Amgen price target raised to $320 from $265 at Wells Fargo"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231012040000"", ""headline"": ""Better Passive Income Snowball: SCHD Or DIVO?"", ""summary"": ""We compare two potential core ETFs for building a passive income snowball. Click here to learn which one is a better fit for the investing strategy.""}, {""date"": ""20231012043200"", ""headline"": ""Jefferies 'optimistic' about Amgen PRMT5 data following embargo"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231012055000"", ""headline"": ""Here\u2019s Why Amgen (AMGN) Outperformed in Q3"", ""summary"": ""Aristotle Capital Management, LLC, an investment management company, released its \u201cValue Equity Strategy\u201d third quarter 2023 investor letter. A copy of the same can be downloaded here. In the third quarter, the fund returned \u20102.99% gross of fees (\u20103.05% net of fees), outperforming the Russell 1000 Value Index\u2019s \u20103.16% return and the S&P 500 Index\u2019s \u20103.27% return. [\u2026]""}, {""date"": ""20231012063200"", ""headline"": ""Stocks to watch out in the Health Care sector as earnings close in"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231012063600"", ""headline"": ""Interesting AMGN Put And Call Options For December 1st"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231012064900"", ""headline"": ""Stocks to watch in the Health Care sector as earnings close in"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231012070300"", ""headline"": ""Check Out What Whales Are Doing With AMGN"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231012090000"", ""headline"": ""Global CAR T-cell Therapy Market Projected to Reach $83 Billion by 2032"", ""summary"": ""PALM BEACH, Fla., Oct. 12, 2023 (GLOBE NEWSWIRE) -- FinancialNewsMedia.com News Commentary - Significant influences driving the CAR T-cell therapy market is a rising demand for model therapeutics for treatment of cancer, increase in prevalence of cancer and an escalating awareness of CAR T-cell therapy medicines. The CAR T-cell therapy market is currently going through a rapid expansion, owing to rapidly expanding clinical trial activities and recent commercialization of CAR-T cell therapy, whic""}, {""date"": ""20231012094000"", ""headline"": ""Amgen: Is There More Upside to Come?"", ""summary"": ""Shares of the biopharmaceutical firm Amgen have been climbing higher. Let's check and see if there is more upside to come.    In this daily bar chart of Amgen, below, I can see that prices have charged higher from a low in early June.""}, {""date"": ""20231012115500"", ""headline"": ""Amgen's (AMGN) Stock Rallies Almost 5% on Broker Upgrade"", ""summary"": ""A Leerink Partner analyst expects accelerating pipeline news flow for Amgen (AMGN).""}, {""date"": ""20231012123800"", ""headline"": ""Amgen Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Shares of Amgen Inc. inched 0.51% higher to $285.04 Thursday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500...""}, {""date"": ""20231012175020"", ""headline"": ""(AMGN) Rises As Market Takes a Dip: Key Facts"", ""summary"": ""In the closing of the recent trading day, Amgen (AMGN) stood at $285.04, denoting a +0.51% change from the preceding trading day.""}, {""date"": ""20231012220600"", ""headline"": ""AMGN Crosses Above 3% Yield Territory"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231013034535"", ""headline"": ""Jefferies Reiterates AMGEN (AMGN) Buy Recommendation"", ""summary"": """"}, {""date"": ""20231013050100"", ""headline"": ""Amgen's PRMT5 drug shows 5 partial respons from 31 patients, STATnews reports"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231013050300"", ""headline"": ""Amgen's PRMT5 drug shows 5 partial responses from 31 patients, STATnews reports"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231013052500"", ""headline"": ""Is Amgen Stock a Buy Now?"", ""summary"": ""The U.S. Federal Trade Commission (FTC) allowed Amgen's (NASDAQ: AMGN) purchase of Horizon Therapeutics to go through last month and the company announced the closing of the deal in a press release last week.  Now that the deal is complete investors can expect some enhanced growth potential on the horizon for Amgen.  The acquisition of Horizon Therapeutics gives Amgen access to an incredibly promising drug called Tepezza, which patients use for thyroid eye disease.""}, {""date"": ""20231013060000"", ""headline"": ""Sanofi reaps rewards of immunology investment with eczema results"", ""summary"": ""Pharmaceutical giant set to take on Amgen with atopic dermatitis treatment.""}, {""date"": ""20231013060300"", ""headline"": ""Ideaya has positive read from Amgen PRMT5 data, says Oppenheimer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231013062400"", ""headline"": ""Tango Therapeutics stock plunges amid data release for Amgen PRMT5 drug"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231013064100"", ""headline"": ""Tango Therapeutics stock plunges amid Amgen PRMT5 drug data (update)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231013083000"", ""headline"": ""Is This Dividend Stock a Screaming Buy After Its Latest Acquisition?"", ""summary"": ""Large companies often turn to acquisitions to jump-start revenue and earnings growth or to speed up research and development, among other reasons.  With that said, let's look at the case of biotech giant Amgen (NASDAQ: AMGN), which just closed a blockbuster acquisition of Horizon Therapeutics.  What does Horizon Therapeutics bring?""}, {""date"": ""20231013085400"", ""headline"": ""Stifel disagrees with negative reaction in Ideaya shares after Amgen data"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231013100000"", ""headline"": ""Amgen: Horizon's Pipeline May Be Too Expensive"", ""summary"": ""We believe that Amgen overpaid for Horizon's pipeline, since most of its upside potential is attributed to price increases instead of the expanding TAM. Read more here.""}, {""date"": ""20231013123800"", ""headline"": ""Amgen Inc. stock outperforms market despite losses on the day"", ""summary"": ""Shares of Amgen Inc. sank 0.33% to $284.10 Friday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...""}, {""date"": ""20231014040600"", ""headline"": ""Johnson & Johnson Stock: Is Now the Time to Sell?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]","{""assetTurnoverTTM"": 0.3207, ""bookValue"": 7656, ""cashRatio"": 2.0491329479768785, ""currentRatio"": 2.8593, ""ebitPerShare"": 3.8848, ""eps"": 3.2156, ""ev"": 168202.84, ""fcfMargin"": 0.3639, ""fcfPerShareTTM"": 17.5308, ""grossMargin"": 0.7385, ""inventoryTurnoverTTM"": 1.4407, ""longtermDebtTotalAsset"": 0.6521, ""longtermDebtTotalCapital"": 0.8667, ""longtermDebtTotalEquity"": 7.7116, ""netDebtToTotalCapital"": 0.3776, ""netDebtToTotalEquity"": 3.3604, ""netMargin"": 0.2506, ""operatingMargin"": 0.3028, ""payoutRatioTTM"": 0.589, ""pb"": 18.6097, ""peTTM"": 18.8311, ""pfcfTTM"": 15.1909, ""pretaxMargin"": 0.2821, ""psTTM"": 5.3097, ""quickRatio"": 2.5629, ""receivablesTurnoverTTM"": 4.6784, ""roaTTM"": 0.0904, ""roeTTM"": 1.2908, ""roicTTM"": 0.123, ""rotcTTM"": 0.147, ""salesPerShare"": 12.8309, ""sgaToSale"": 0.2615, ""totalDebtToEquity"": 7.8981, ""totalDebtToTotalAsset"": 0.6679, ""totalDebtToTotalCapital"": 0.8876, ""totalRatio"": 1.0924, ""period"": ""2023-09-30""}"
40,2023-10-15,275.80419921875,2023-10-22,270.66864013671875,-0.018620307800165325,D2,"[{""date"": ""20231015233800"", ""headline"": ""Amgen resumed with an Equal Weight at Morgan Stanley"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231016000700"", ""headline"": ""Amgen\u2019s Future: Evaluating Growth, Pipeline Progress and Risks Post-Horizon Acquisition"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231016021200"", ""headline"": ""Xeris Biopharma  tightens FY23 revenue view to $155M-$165M from $145M-$165M"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231016064428"", ""headline"": ""AbbVie: Successfully Navigating Humira's Patent Cliff With 4% Yield And 270% DGR Since 2014"", ""summary"": ""Despite declining Humira sales, AbbVie remains resilient, focusing on new therapies, M&A, and R&D for sustained growth. Find out why ABBV stock is a Hold.""}, {""date"": ""20231016070200"", ""headline"": ""$100 Invested In Amgen 15 Years Ago Would Be Worth This Much Today"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231016090000"", ""headline"": ""AMGEN TO PRESENT NEW RESEARCH FROM ONCOLOGY PORTFOLIO AND PIPELINE AT ESMO 2023"", ""summary"": ""Amgen (NASDAQ:AMGN) today announced the presentation of new data across its broad oncology portfolio and pipeline at the European Society for Medical Oncology (ESMO) Congress 2023, taking place from October 20-24 in Madrid. Results from Amgen-sponsored and collaborative studies, including two late-breaking oral presentations, will feature data in a range of tough-to-treat cancers.""}, {""date"": ""20231016090005"", ""headline"": ""Why Investors Need to Take Advantage of These 2 Medical Stocks Now"", ""summary"": ""The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.""}, {""date"": ""20231016121010"", ""headline"": ""Will Amgen (AMGN) Beat Estimates Again in Its Next Earnings Report?"", ""summary"": ""Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.""}, {""date"": ""20231016123700"", ""headline"": ""Amgen Inc. stock rises Monday, still underperforms market"", ""summary"": ""Shares of Amgen Inc. inched 0.98% higher to $286.88 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P...""}, {""date"": ""20231016152500"", ""headline"": ""Investors Shun Dividend-Paying Stocks"", ""summary"": ""One aspect of the equity market advance this year is investors' heightened focus on a handful of stocks some are referring to as Magnificent Seven. Read more here.""}, {""date"": ""20231016223700"", ""headline"": ""Amgen Unusual Options Activity For October 17"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231016235500"", ""headline"": ""William Blair healthcare/biotech analysts hold analyst/industry conference call"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231017041600"", ""headline"": ""Amgen price target raised to $310 from $280 at Argus"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231017065527"", ""headline"": ""Morgan Stanley Reiterates AMGEN (AMGN) Equal-Weight Recommendation"", ""summary"": """"}, {""date"": ""20231017090006"", ""headline"": ""Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know"", ""summary"": ""Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.""}, {""date"": ""20231017114011"", ""headline"": ""PBYI vs. AMGN: Which Stock Is the Better Value Option?"", ""summary"": ""PBYI vs. AMGN: Which Stock Is the Better Value Option?""}, {""date"": ""20231017163000"", ""headline"": ""Dividend Income Update September 2023"", ""summary"": ""With the start of the final quarter of 2023, it\u2019s time to take a look back at my previous month of dividend income.""}, {""date"": ""20231017205541"", ""headline"": ""Argus Research Maintains AMGEN (AMGN) Buy Recommendation"", ""summary"": """"}, {""date"": ""20231018044500"", ""headline"": ""Seagen abstract hits best case scenario, says RBC Capital"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231018083900"", ""headline"": ""10 Health Care Stocks Whale Activity In Today's Session"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231018112000"", ""headline"": ""5 Biotech Stocks Set to Outpace Q3 Earnings Estimates"", ""summary"": ""Let us look at some biotech stocks, AMGN, BIIB, GSK, PRTA and VRTX, which are poised to beat on third-quarter earnings.""}, {""date"": ""20231018123700"", ""headline"": ""Amgen Inc. stock outperforms competitors despite losses on the day"", ""summary"": ""Shares of Amgen Inc. slid 0.30% to $283.58 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20231018175017"", ""headline"": ""Amgen (AMGN) Stock Moves -0.3%: What You Should Know"", ""summary"": ""Amgen (AMGN) closed the most recent trading day at $283.58, moving -0.3% from the previous trading session.""}, {""date"": ""20231019020100"", ""headline"": ""Invest with Confidence: Intrinsic Value Unveiled of Amgen Inc"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231019035700"", ""headline"": ""Amgen\u2019s Growth Potential: A Comprehensive Analysis of Stock Rally, EPS Expectations, and Emerging Catalysts"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231019061800"", ""headline"": ""Dow drops nearly 100 points on losses in shares of Merck, Amgen"", ""summary"": ""Shares of Merck and Amgen are posting losses Thursday morning, dragging the Dow Jones Industrial Average into negative territory. The Dow was most recently...""}, {""date"": ""20231019072400"", ""headline"": ""See Which Of The Latest 13F Filers Holds Amgen"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231019082500"", ""headline"": ""Baron Health Care Fund Q3 2023 Shareholder Letter"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231019123800"", ""headline"": ""Amgen Inc. stock underperforms Thursday when compared to competitors"", ""summary"": ""Shares of Amgen Inc. shed 1.05% to $280.60 Thursday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20231019160000"", ""headline"": ""AMGEN TO WEBCAST INVESTOR CALL AT ESMO 2023"", ""summary"": ""Amgen (NASDAQ:AMGN) today announced that it will host a webcasted call for the investment community at 8:00 a.m. ET on Tuesday, Oct. 24, 2023 following the presentation of new data from Amgen's innovative oncology portfolio including AMG 193 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 and data from tarlatamab, xaluritamig, and LUMAKRAS\u00ae (sotorasib) that will be presented at the European Society for Medical Oncology (ESMO) Congress 2023. David""}, {""date"": ""20231019220200"", ""headline"": ""Catalyst Watch: Tech earnings blitz, Qualcomm event and Stellantis reveals"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231019230000"", ""headline"": ""Bond Prices Are Slumping Again. Consider These Dividend ETFs Instead."", ""summary"": ""Morningstar has identified four dividend funds that hold quality companies and have a proven record.""}, {""date"": ""20231020012200"", ""headline"": ""Amgen price target raised to $300 from $290 at Oppenheimer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231020020600"", ""headline"": ""Amgen reinstated with a Neutral at JPMorgan"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231020030400"", ""headline"": ""Amgen presents data from global Phase 2 DeLLphi-301 study"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231020043700"", ""headline"": ""SolarEdge downgraded, Crocs upgraded: Wall Street's top analyst calls"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231020045600"", ""headline"": ""Amgen hails new tarlatamab data in small cell lung cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231020080000"", ""headline"": ""AMGEN PRESENTS NEW TARLATAMAB DATA IN SMALL CELL LUNG CANCER"", ""summary"": ""Amgen (NASDAQ:AMGN) today announced results from the global Phase 2 DeLLphi-301 study, evaluating tarlatamab, an investigational delta-like ligand 3 (DLL3) targeting BiTE\u00ae (bispecific T-cell engager) molecule, in patients with advanced stage small cell lung cancer (SCLC) who had failed two or more prior lines of treatment. The data are being presented today at 3:20 PM CEST at a Proffered Paper session as a late-breaking oral presentation (LBA92) during the European Society for Medical Oncology (""}, {""date"": ""20231020083000"", ""headline"": ""Amgen posts Phase 2 data for targeted immunotherapy in lung cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231020123700"", ""headline"": ""Amgen Inc. stock outperforms market despite losses on the day"", ""summary"": ""Shares of Amgen Inc. dropped 0.64% to $278.81 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20231020144100"", ""headline"": ""Top Stock Reports for Apple, Amgen & Becton, Dickinson"", ""summary"": ""Today's Research Daily features new research reports on 12 major stocks, including Apple Inc. (AAPL), Amgen Inc. (AMGN) and Becton, Dickinson and Company (BDX).""}, {""date"": ""20231020214342"", ""headline"": ""Oppenheimer Maintains AMGEN (AMGN) Outperform Recommendation"", ""summary"": """"}, {""date"": ""20231020214342"", ""headline"": ""JP Morgan Reiterates AMGEN (AMGN) Neutral Recommendation"", ""summary"": """"}, {""date"": ""20231021231300"", ""headline"": ""Ambrx Biopharma 'the real winner in prostate' at ESMO, says Oppenheimer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231021234500"", ""headline"": ""Amgen presents data from the global Phase 3 CodeBreaK 300 trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231022103000"", ""headline"": ""AMGEN PRESENTS NEW LUMAKRAS\u00ae (SOTORASIB) PLUS VECTIBIX\u00ae (PANITUMUMAB) DATA IN PATIENTS WITH KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER"", ""summary"": ""Amgen (NASDAQ:AMGN) today announced data from the global Phase 3 CodeBreaK 300 trial evaluating two doses of LUMAKRAS\u00ae (sotorasib) (960 mg or 240 mg) in combination with Vectibix\u00ae (panitumumab). Both doses demonstrated a statistically significant superiority in progression-free survival (PFS) over the investigator's choice of therapy in patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC). The results are being presented today at the Presidential Symposium 2 sessio""}]",{}
41,2023-10-22,270.66864013671875,2023-10-29,253.93206787109375,-0.06183417575516359,D5+,"[{""date"": ""20231021231300"", ""headline"": ""Ambrx Biopharma 'the real winner in prostate' at ESMO, says Oppenheimer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231021234500"", ""headline"": ""Amgen presents data from the global Phase 3 CodeBreaK 300 trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231022103000"", ""headline"": ""AMGEN PRESENTS NEW LUMAKRAS\u00ae (SOTORASIB) PLUS VECTIBIX\u00ae (PANITUMUMAB) DATA IN PATIENTS WITH KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER"", ""summary"": ""Amgen (NASDAQ:AMGN) today announced data from the global Phase 3 CodeBreaK 300 trial evaluating two doses of LUMAKRAS\u00ae (sotorasib) (960 mg or 240 mg) in combination with Vectibix\u00ae (panitumumab). Both doses demonstrated a statistically significant superiority in progression-free survival (PFS) over the investigator's choice of therapy in patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC). The results are being presented today at the Presidential Symposium 2 sessio""}, {""date"": ""20231022233200"", ""headline"": ""Looking At Amgen's Recent Unusual Options Activity"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231023021200"", ""headline"": ""Amgen's Lumakras shows progression-free survival improvement in trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231023043200"", ""headline"": ""AbbVie (ABBV) to Report Q3 Earnings: What's in the Cards?"", ""summary"": ""AbbVie's (ABBV) Q3 performance will likely reflect its newer immunotherapy drugs trying to compensate for declining Humira sales following the loss of U.S. exclusivity.""}, {""date"": ""20231023063200"", ""headline"": ""The Zacks Analyst Blog Highlights Apple, Amgen, Becton, Dickinson, UnitedHealth and Verisk"", ""summary"": ""Apple, Amgen, Becton, Dickinson, UnitedHealth and Verisk are included in this Analyst Blog.""}, {""date"": ""20231023123700"", ""headline"": ""Amgen Inc. stock falls Monday, underperforms market"", ""summary"": ""Shares of Amgen Inc. shed 2.06% to $273.06 Monday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20231023142600"", ""headline"": ""Circling Bank On Tango Therapeutics"", ""summary"": ""We are circling back on clinical stage developmental concern Tango Therapeutics, Inc. for the first time since November 2022. Read more about TNGX stock here.""}, {""date"": ""20231023211000"", ""headline"": ""Video: Dow Movers: AMGN, VZ"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231023221300"", ""headline"": ""Amgen Layoffs 2023: What to Know About the Latest AMGN Job Cuts"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231023230600"", ""headline"": ""Amgen declares $2.13 dividend"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231024080600"", ""headline"": ""Amgen reportedly to cut 350 Horizon employees in wake of merger"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231024085000"", ""headline"": ""Amgen to Lay Off 350 U.S. Employees of Horizon Therapeutics"", ""summary"": ""By Joseph Walker Amgen is laying off about 350 U.S. employees of Horizon Therapeutics, the drugmaker that Amgen bought in a $27.8 billion deal that closed...""}, {""date"": ""20231024090347"", ""headline"": ""Hematology/Oncology Update ESMO 2023"", ""summary"": ""The following slide deck was published by Amgen Inc.""}, {""date"": ""20231024091500"", ""headline"": ""3 Biotech Stocks With Decent Dividend for a Steady Return"", ""summary"": ""Here we pick three medical device stocks, AbbVie (ABBV), Amgen (AMGN) and Gilead Sciences (GILD), which have a solid five-year dividend growth history.""}, {""date"": ""20231024100052"", ""headline"": ""Amgen (AMGN) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release"", ""summary"": ""Amgen (AMGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.""}, {""date"": ""20231024110259"", ""headline"": ""12 Defensive Healthcare Dividend Stocks To Invest In"", ""summary"": ""In this article, we discuss 12 defensive healthcare dividend stocks to invest in. You can skip our detailed analysis of the healthcare sector and dividend stocks, and go directly to read 5 Defensive Healthcare Dividend Stocks To Invest In. The healthcare sector has undergone significant evolution over the years, especially after the pandemic. Advances in [\u2026]""}, {""date"": ""20231024111908"", ""headline"": ""Amgen Inc. (AMGN) Amgen Conference Call Following European Society for Medical Oncology Congress 2023 Transcript"", ""summary"": ""Amgen Inc. (NASDAQ:NASDAQ:AMGN) Amgen Conference Call Following European Society for Medical Oncology Congress 2023 October 24, 2023 8:00 AM ETCompany...""}, {""date"": ""20231024123800"", ""headline"": ""Amgen Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Amgen Inc. advanced 1.12% to $276.12 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...""}, {""date"": ""20231024160000"", ""headline"": ""AMGEN ANNOUNCES 2023 FOURTH QUARTER DIVIDEND"", ""summary"": ""Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.13 per share dividend for the fourth quarter of 2023. The dividend will be paid on December 8, 2023, to all stockholders of record as of the close of business on November 17, 2023.""}, {""date"": ""20231024175018"", ""headline"": ""Amgen (AMGN) Outperforms Broader Market: What You Need to Know"", ""summary"": ""In the latest trading session, Amgen (AMGN) closed at $276.12, marking a +1.12% move from the previous day.""}, {""date"": ""20231024214500"", ""headline"": ""These Gene-Editing Stocks Are Survivors. Take Another Look."", ""summary"": ""The market has nearly abandoned many of the biotech start-ups it funded in the excitement of the first Covid-19 vaccines in 2021.""}, {""date"": ""20231024234800"", ""headline"": ""Amgen\u2019s Promising Oncology Pipeline Progress and Favorable Clinical Trials Fuel Analyst\u2019s Buy Rating"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231025013600"", ""headline"": ""Amgen price target raised to $310 from $300 at Oppenheimer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231025022100"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Danaher (DHR) and Sanofi (OtherSNYNF)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231025023300"", ""headline"": ""Amgen price target raised to $336 from $293 at TD Cowen"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231025042809"", ""headline"": ""20 Countries with Lowest Rates of Cancer"", ""summary"": ""In this article, we will be taking a look at the 20 countries with lowest rates of cancer. If you want to skip our analysis of the oncology industry, then head straight to 5 Countries with Lowest Rates of Cancer. Cancer\u2014 a disease in which some of the body\u2019s cells grow uncontrollably and spread to [\u2026]""}, {""date"": ""20231025044900"", ""headline"": ""USA Compression and Disney have been highlighted as Zacks Bull and Bear of the Day"", ""summary"": ""USA Compression and Disney have been highlighted as Zacks Bull and Bear of the Day.""}, {""date"": ""20231025070100"", ""headline"": ""Video: Daily Dividend Report: AMGN,ROL,APH,WFC,SWK"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231025072600"", ""headline"": ""Amgen (AMGN) to Report Q3 Earnings: Will It Beat Estimates?"", ""summary"": ""Volume growth from Amgen's (AMGN) key drugs like Prolia, Repatha and Evenity, among others, is expected to have been partially offset by biosimilar/generic competition for mature drugs.""}, {""date"": ""20231025084200"", ""headline"": ""10 Health Care Stocks With Whale Alerts In Today's Session"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231025100219"", ""headline"": ""UniQure (QURE) Expected to Beat Earnings Estimates: Should You Buy?"", ""summary"": ""UniQure (QURE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.""}, {""date"": ""20231025112040"", ""headline"": ""Oppenheimer Maintains AMGEN (AMGN) Outperform Recommendation"", ""summary"": """"}, {""date"": ""20231025123700"", ""headline"": ""Amgen Inc. stock underperforms Wednesday when compared to competitors"", ""summary"": ""Shares of Amgen Inc. slid 1.43% to $272.16 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20231025160000"", ""headline"": ""AMGEN ANNOUNCES WEBCAST OF 2023 THIRD QUARTER FINANCIAL RESULTS"", ""summary"": ""Amgen (NASDAQ:AMGN) today announced that it will report its third quarter financial results on Tuesday, October 31, 2023, before the opening of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 5:00 a.m. PT. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team.""}, {""date"": ""20231026014800"", ""headline"": ""ImmunoGen 'should rank high on list' of possible M&A targets, says Guggenheim"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231026070000"", ""headline"": ""A large international study of migraine reveals new biological pathways for treatment"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231026073000"", ""headline"": ""3 Pharma Stocks That Are Screaming Buys in October"", ""summary"": ""It hasn't been the easiest of years for Johnson & Johnson (NYSE: JNJ), Amgen (NASDAQ: AMGN) and Gilead Sciences (NASDAQ: GILD).  Continued uncertainty regarding talc lawsuits is weighing on Johnson & Johnson.  Amgen's huge pipeline hasn't been fully appreciated by the market, and Gilead's settlement of an antitrust lawsuit resulted in lowering yearly earnings per share guidance.""}, {""date"": ""20231026123700"", ""headline"": ""Amgen Inc. stock outperforms market despite losses on the day"", ""summary"": ""Shares of Amgen Inc. dropped 0.90% to $269.71 Thursday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20231026215600"", ""headline"": ""Amgen\u2019s Promising Oncology Pipeline: A Buy Rating Driven by T-Cell Engagers\u2019 Potential"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231026220300"", ""headline"": ""Catalyst Watch: Apple earnings, Fed policy meeting, jobs report"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231026224100"", ""headline"": ""Analysts Conflicted on These Healthcare Names: Amgen (AMGN), Immutep (IMMP) and Bristol-Myers Squibb (BMY)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231026233600"", ""headline"": ""Bears Roam Wall Street As Middle East Conflict, Earnings Outlook Raise Concerns Despite Strong Q3 US Economic Growth: This Week In Markets"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231027074650"", ""headline"": ""UPDATE 4-AbbVie takes $2.1 bln charge on cancer drug ahead of US price negotiation"", ""summary"": ""AbbVie, girding for government price negotiations on its big-selling cancer drug Imbruvica, on Friday disclosed a $2.1 billion charge related to an expected drop in revenue once the new price for U.S. Medicare patients goes into effect.  The Illinois-based drugmaker's leukemia pill in August was selected as one of the 10 drugs subject to the first-ever price negotiations by U.S. Medicare insurance plans with a stated government goal of saving $25 billion per year on drug costs by 2031.  While new prices for the first 10 drugs have yet to be negotiated and will not go into effect until 2026, AbbVie said it had used an undisclosed placeholder price that led it to estimate \""a significant decrease in the estimated future cash flows\"" from the drug.""}, {""date"": ""20231027075653"", ""headline"": ""Xencor: Data In Early 2024 Could Bring Shareholder Value"", ""summary"": ""Xencor is expected to release data from a phase 2 study in early 2024 targeting patients with mCRPC and gynecological cancers. Read more about XNCR stock here.""}, {""date"": ""20231027123700"", ""headline"": ""Amgen Inc. stock falls Friday, underperforms market"", ""summary"": ""Shares of Amgen Inc. shed 3.02% to $261.57 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20231027145250"", ""headline"": ""Apple Headlines Earnings Calendar With Chip Titan AMD, Amgen Also Set To Report"", ""summary"": ""Apple stock is below its 200-day line with earnings due. Advanced Micro Devices and Amgen also report next week.""}, {""date"": ""20231028114350"", ""headline"": ""Microsoft Leads These 5 Dow Jones Stocks Near Buy Points"", ""summary"": ""Microsoft, one of just two Magnificent Seven stocks to move higher last week, leads this watchlist of five Dow Jones stocks. near buy points.""}, {""date"": ""20231029033000"", ""headline"": ""Earnings week ahead: Apple, AMD, Pfizer, McDonald's, Starbucks and more"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231029063000"", ""headline"": ""2 Dow Jones Dividend Stocks to Buy Hand Over Fist Right Now"", ""summary"": ""Dividend stocks have not performed particularly well in 2023, and for good reason.  With many financial institutions offering safer alternatives, such as money market accounts and certificates of deposit, with annualized rates above 5%, there's been little reason for investors to stomach the volatility associated with equities.  Dividend stocks have a long history of outperforming most other asset classes over holding periods of 20 years or longer.""}, {""date"": ""20231029070500"", ""headline"": ""Pharma, PBMs spar over rising drug costs amid public scrutiny"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
42,2023-10-29,253.93206787109375,2023-11-05,261.9800109863281,0.03169329176384239,U4,"[{""date"": ""20231029033000"", ""headline"": ""Earnings week ahead: Apple, AMD, Pfizer, McDonald's, Starbucks and more"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231029063000"", ""headline"": ""2 Dow Jones Dividend Stocks to Buy Hand Over Fist Right Now"", ""summary"": ""Dividend stocks have not performed particularly well in 2023, and for good reason.  With many financial institutions offering safer alternatives, such as money market accounts and certificates of deposit, with annualized rates above 5%, there's been little reason for investors to stomach the volatility associated with equities.  Dividend stocks have a long history of outperforming most other asset classes over holding periods of 20 years or longer.""}, {""date"": ""20231029070500"", ""headline"": ""Pharma, PBMs spar over rising drug costs amid public scrutiny"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231029224600"", ""headline"": ""Apple, AMD, Palantir Earnings On Deck This Week As Market Seeks Positive Catalysts In Fed Decision Week"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231029231300"", ""headline"": ""Amgen slated to release first earnings report since Horizon merger on Tuesday"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231030050400"", ""headline"": ""Earnings Outlook For Amgen"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231030052541"", ""headline"": ""11 Best Immunotherapy Stocks To Buy Now"", ""summary"": ""In this article, we discuss 11 of the best immunotherapy stocks to buy now. If you want to skip our detailed discussion on the cancer and oncology industry, head directly to the 5 Best Immunotherapy Stocks To Buy Now. The global oncology landscape is continually transforming, driven by persistent efforts to explore, create, and deliver [\u2026]""}, {""date"": ""20231030054635"", ""headline"": ""11 Best Pharma Stocks To Buy Now"", ""summary"": ""In this article, we discuss the 12 best pharma stocks to buy now. You can skip our detailed analysis of the pharmaceutical sector and its outlook this year, and go directly to read the 5 Best Pharma Stocks To Buy Now. Shortly following the onset of the COVID-19 pandemic, it became evident that the world [\u2026]""}, {""date"": ""20231030060300"", ""headline"": ""Notable earnings before Tuesday's open"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231030070000"", ""headline"": ""SCHD Just Fell Off A Cliff: An Inside Look"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231030073927"", ""headline"": ""Schwab Dividend ETF (SCHD) Just Fell Off A Cliff: An Inside Look"", ""summary"": ""SCHD ETF faced a drop in value due to selling pressure in top holdings. Look for the trend to reverse over time due to the high quality nature of the holdings.""}, {""date"": ""20231030082600"", ""headline"": ""Notable companies reporting before tomorrow's open"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231030113700"", ""headline"": ""Drug, Biotech Stocks' Q3 Earnings Due on Oct 31: AMGN, PFE, INCY"", ""summary"": ""Let's take a look at three biotech/drug companies, AMGN, PFE and INCY, slated to release quarterly results on Oct 31.""}, {""date"": ""20231030123800"", ""headline"": ""Amgen Inc. stock rises Monday, still underperforms market"", ""summary"": ""Shares of Amgen Inc. inched 0.62% higher to $263.19 Monday, on what proved to be an all-around favorable trading session for the stock market, with the S&P...""}, {""date"": ""20231030211600"", ""headline"": ""Noteworthy Tuesday Option Activity: AMGN, CE, REGN"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231030234000"", ""headline"": ""What You Missed On Wall Street On Tuesday"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231031004100"", ""headline"": ""Analysts Conflicted on These Healthcare Names: Amgen (AMGN), Qiagen (QGEN) and HCA Healthcare (HCA)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231031020100"", ""headline"": ""Amgen reports Q3 adjusted EPS $4.96, consensus $4.39"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231031020300"", ""headline"": ""Amgen narrows FY23 adjusted EPS view to $18.20-$18.80 from $17.80-$18.80"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231031021100"", ""headline"": ""Amgen sees FY23 CapEx about $950M"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231031022000"", ""headline"": ""Amgen\u2019s stock jumps premarket after earnings beat and company again raises guidance"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231031022500"", ""headline"": ""Amgen reports Q3 total product sales up 5% y/y"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231031024100"", ""headline"": ""Amgen Non-GAAP EPS of $4.96 beats by $0.28, revenue of $6.9B misses by $50M"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231031024700"", ""headline"": ""U.S. Stocks Poised To Extend Gains As Fed Meeting Gets Underway; Why This Analyst Expects 'Young Bull Market' To Remain Alive"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231031025800"", ""headline"": ""Amgen stock gains after lifting annual outlook"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231031030000"", ""headline"": ""Amgen 3Q Profit Sinks On Discontinued Development Charge"", ""summary"": ""By Ben Glickman Amgen's third-quarter profit sank on an impairment charge related to discontinued development of one of its drug candidates. The Thousand...""}, {""date"": ""20231031030200"", ""headline"": ""Charlie Munger says there\u2019s not much \u2018low-hanging fruit left\u2019 as he discusses Apple, Costco vs. Walmart, and EVs"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231031030800"", ""headline"": ""Amgen Lifts FY23 Guidance After 3Q Adjusted Profit Tops Estimates"", ""summary"": ""By Ben Glickman Amgen narrowed its full-year guidance for adjusted profit and raised its revenue guidance after third-quarter adjusted profit topped Wall...""}, {""date"": ""20231031031700"", ""headline"": ""Amgen: Q3 Earnings Snapshot"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231031031900"", ""headline"": ""Amgen's stock hit by expectations its obesity pipeline is facing a longer wait"", ""summary"": ""Amgen Inc.'s stock fell 3.3% Tuesday despite an earnings beat and raised guidance. Obesity drugs were to blame.""}, {""date"": ""20231031033700"", ""headline"": ""Amgen\u2019s Stock Rated as Buy: Promising Earnings, HZNP Acquisition Impact, and Product Pipeline Strengths"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231031035000"", ""headline"": ""Amgen in charts: Sales of Prolia, XGEVA surge on higher prices; Enbrel, Otezla fall Y/Y"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231031035000"", ""headline"": ""5 stocks to watch on Tuesday: Sarepta Therapeutics, Pfizer, AMD and more"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231031040400"", ""headline"": ""Amgen Boosts Revenue Guidance, but the Stock Is Falling"", ""summary"": ""The biotechnology company beat third-quarter adjusted earnings estimates but fell a bit short on sales.""}, {""date"": ""20231031041700"", ""headline"": ""Amgen (NASDAQ:AMGN) Delivers Better-than-Expected Q3 Earnings"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231031042900"", ""headline"": ""Amgen ups annual revenue guidance despite quarterly income dip"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231031045800"", ""headline"": ""Amgen stock erases gains despite outlook boost (update)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231031053100"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), AbbVie (ABBV) and Crispr Therapeutics AG (CRSP)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231031054500"", ""headline"": ""Dow drops 85 points on losses for Caterpillar, Amgen shares"", ""summary"": ""Behind negative returns for shares of Caterpillar and Amgen, the Dow Jones Industrial Average is falling Tuesday morning. The Dow was most recently trading...""}, {""date"": ""20231031062600"", ""headline"": ""Amgen says study of AMG 340 in mCRPC will be discontinued"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231031070000"", ""headline"": ""AMGEN REPORTS THIRD QUARTER FINANCIAL RESULTS"", ""summary"": ""Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 20231.""}, {""date"": ""20231031070500"", ""headline"": ""Treasury Announcement More Important Than Fed's, Japan Abandons Yield Control, Tesla Under $200"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231031071017"", ""headline"": ""Amgen third-quarter sales rise 5%; profit up before charge"", ""summary"": ""Amgen, which earlier this month acquired Horizon Therapeutics for $27.8 billion, on Tuesday said its third-quarter product sales rose 5% as double-digit volume growth was offset by lower prices.  Amgen said it would discuss sales of Horizon's drugs on a conference call with analysts and investors, but raised its post-acquisition forecast for full-year sales to between $28 billion and $28.4 billion from a previous estimate of $26.6 billion to $27.4 billion.  Wall Street analysts, on average, have forecast 2023 earnings of $18.47 per share on revenue of $28 billion, according to LSEG data.""}, {""date"": ""20231031075841"", ""headline"": ""UPDATE 1-Amgen third-quarter sales rise 5%; profit up before charge"", ""summary"": ""Amgen, which earlier this month acquired Horizon Therapeutics for $27.8 billion, on Tuesday said its third-quarter product sales rose 5% as double-digit volume growth was offset by lower prices.  Amgen said it would discuss sales of Horizon's drugs on a conference call with analysts and investors, but raised its post-acquisition forecast for full-year sales to between $28 billion and $28.4 billion from a previous estimate of $26.6 billion to $27.4 billion.  Wall Street analysts, on average, have forecast 2023 earnings of $18.47 per share on revenue of $28 billion, according to LSEG data.""}, {""date"": ""20231031080000"", ""headline"": ""Amgen\u2019s stock hit by expectations its obesity pipeline is facing a longer wait"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231031080400"", ""headline"": ""Amgen Boosts Revenue Guidance. But the Stock Trades Lower."", ""summary"": ""The biotechnology company beat third-quarter adjusted earnings estimates but fell a bit short on sales.""}, {""date"": ""20231031081500"", ""headline"": ""Stocks Lack Direction As Traders Remain Cautious Ahead Of Fed Meeting, Nvidia Falls On Export Controls: What's Driving Markets Tuesday?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231031082506"", ""headline"": ""Amgen (AMGN) Q3 Earnings Top Estimates"", ""summary"": ""Amgen (AMGN) delivered earnings and revenue surprises of 6.67% and 0.80%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?""}, {""date"": ""20231031083254"", ""headline"": ""Amgen Inc (AMGN) Q3 2023 Earnings: Revenue Up 4% to $6.9 Billion, GAAP EPS Down 19% to $3.22"", ""summary"": ""Amgen Inc (AMGN) reports Q3 2023 financial results, highlighting growth in product sales and pipeline progress""}, {""date"": ""20231031083800"", ""headline"": ""10 Health Care Stocks Whale Activity In Today's Session"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231031091504"", ""headline"": ""Amgen Inc. (AMGN) Q3 2023 Earnings Call Transcript"", ""summary"": ""Amgen Inc. (NASDAQ:NASDAQ:AMGN) Q3 2023 Earnings Conference Call October 31, 2023 8:00 AM ETCompany ParticipantsJustin Claeys - VP, IRRobert Bradway -...""}, {""date"": ""20231031091616"", ""headline"": ""Amgen Inc. 2023 Q3 - Results - Earnings Call Presentation"", ""summary"": ""The following slide deck was published by Amgen Inc.""}, {""date"": ""20231031093028"", ""headline"": ""Here's What Key Metrics Tell Us About Amgen (AMGN) Q3 Earnings"", ""summary"": ""Although the revenue and EPS for Amgen (AMGN) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.""}, {""date"": ""20231031113000"", ""headline"": ""Amgen (AMGN) Beats on Q3 Earnings Beat, Lags Sales, Ups View"", ""summary"": ""Amgen (AMGN) beats Q3 estimates for earnings but misses on sales. Following the acquisition of Horizon Therapeutics, it raises earnings and sales guidance for 2023.""}, {""date"": ""20231031121800"", ""headline"": ""NEW YORK MARKET CLOSE: Stocks up with Fed likely to extend rate pause"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231031123500"", ""headline"": ""Never Mind Covid, Investors Want a Pfizer Obesity Pill"", ""summary"": ""It is little wonder, then, that investors were hoping Pfizer could jump to the winning camp with an obesity pill.  \u201cNot one mention [of danuglipron] in the prepared remarks from Pfizer,\u201d noted  Will Sevush,  a healthcare strategist for Jefferies.  Before today\u2019s earnings,  David Risinger,  a Leerink Partners analyst, had written that Pfizer might even release data from its mid-stage study alongside the earnings results as soon as Tuesday.""}, {""date"": ""20231031123800"", ""headline"": ""Amgen Inc. stock falls Tuesday, underperforms market"", ""summary"": ""Shares of Amgen Inc. slid 2.85% to $255.70 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20231031125601"", ""headline"": ""Amgen's obesity drug plans, outlook for 2024"", ""summary"": ""Amgen (AMGN) reported third-quarter earnings that beat expectations and raised its full-year revenue guidance. The company recently completed its acquisition of Horizon Therapeutics, which brings its drug Tepezza to Amgen. Amgen is also looking to move into the obesity drug space which has garnered much attention from Wall Street. Yahoo Finance Senior Reporter Anjalee Khemlani interviewed Amgen CFO Peter Griffith to get his take on the company's performance. When it comes to the obesity space, Griffith says, \""what I am delighted to announce is that we've completed enrollment in Maridebart Cafraglutide, or we call it 'Mari', formerly AMG 133, for the treatment of obesity, in phase 2. We've got over 570 patients in the cohort, with and without diabetes, and so that's the center of the platform that we want to build on with obesity.\"" For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.""}, {""date"": ""20231031130000"", ""headline"": ""GSK Reports Earnings Wednesday. Here\u2019s What to Expect."", ""summary"": ""The company will for the first time report sales of Arexvy, its new RSV vaccine that launched this fall.""}, {""date"": ""20231031131851"", ""headline"": ""Markets Edge Higher at Midday Ahead of Wednesday's Fed Decision"", ""summary"": ""U.S. equities edged higher at midday on Tuesday, Oct. 31, 2023 ahead of Wednesday's decision by the Federal Reserve, with policymakers widely expected to keep interest rates steady.""}, {""date"": ""20231031133628"", ""headline"": ""Amgen Tumbles After Scrapping A $900 Million Prostate Cancer Drug"", ""summary"": ""Amgen handily beat earnings forecasts Tuesday, but Amgen stock tumbled after the company scrapped an experimental prostate cancer treatment.""}, {""date"": ""20231031150500"", ""headline"": ""Amgen gets FDA approval for its inflammatory diseases treatment Wezlana"", ""summary"": ""Amgen has received approval from the U.S. Food and Drug Administration for Wezlana, its treatment for multiple inflammatory diseases.""}, {""date"": ""20231031170020"", ""headline"": ""S&P 500 Gains and Losses Today: Arista Networks Results and Guidance Beat Estimates"", ""summary"": ""The S&P 500 gained 0.65% on Tuesday, Oct. 31, 2023, ahead of Wednesday's Federal Reserve decision, more key earnings news, and Friday's jobs report.""}, {""date"": ""20231031211300"", ""headline"": ""Fear & Greed Index Remains In 'Fear' Zone Ahead Of Fed's Decision"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231031212200"", ""headline"": ""These Analysts Revise Their Forecasts On Amgen After Q3 Results"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231101001237"", ""headline"": ""Q3 2023 Amgen Inc Earnings Call"", ""summary"": ""Q3 2023 Amgen Inc Earnings Call""}, {""date"": ""20231101013900"", ""headline"": ""Amgen cleared in U.S. to market biosimilar to J&J\u2019s Stelara"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231101014100"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Biogen (BIIB) and Vertex Pharmaceuticals (VRTX)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231101020000"", ""headline"": ""Amgen price target lowered to $268 from $272 at UBS"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231101020200"", ""headline"": ""Beyond Market Price: Uncovering Amgen Inc's Intrinsic Value"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231101022700"", ""headline"": ""Hold Rating on Amgen: Balancing Expectations with Underperformance and Future Prospects"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231101035900"", ""headline"": ""GLOBAL BROKER RATINGS: JPMorgan cuts BP to 'underweight'"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231101043700"", ""headline"": ""Positive Prospects for Amgen: A Comprehensive Analysis of Q3 Performance and Future Catalysts"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231101080500"", ""headline"": ""Company News for Nov 01, 2023"", ""summary"": ""Companies In The Article Are: AMGN, NVDA, RGEN, COCO""}, {""date"": ""20231101090000"", ""headline"": ""AMGEN TO PRESENT DATA AT ACR 2023 ACROSS EXPANDED RHEUMATOLOGY PIPELINE AND PORTFOLIO"", ""summary"": ""Amgen (NASDAQ:AMGN) today announced the presentation of new scientific and clinical research across its expanded rheumatology pipeline and portfolio, following the recent acquisition of Horizon Therapeutics. More than 20 abstracts will be presented during the American College of Rheumatology (ACR) Convergence 2023, taking place Nov. 10-15, in San Diego.""}, {""date"": ""20231101103148"", ""headline"": ""Amgen Inc. (NASDAQ:AMGN) Q3 2023 Earnings Call Transcript"", ""summary"": ""Amgen Inc. (NASDAQ:AMGN) Q3 2023 Earnings Call Transcript October 31, 2023 Operator: My name is Julianne, and I\u2019ll be your conference facilitator today for Amgen\u2019s Third Quarter 2023 Financial Results Conference Call. All lines have been placed on mute to prevent any background noise. There will be a question-and-answer session at the conclusion of the [\u2026]""}, {""date"": ""20231101130000"", ""headline"": ""Novo Nordisk Reports Earnings Soon. Wegovy and Ozempic Will Be in Focus."", ""summary"": ""The report comes amid what has been a surprisingly grim two weeks for the pharmaceutical stocks.""}, {""date"": ""20231101212100"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (RANI) and Amgen (AMGN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231101220300"", ""headline"": ""Amgen Wins Big With FDA, Analyst Sees Soaring Potential"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231102000900"", ""headline"": ""What You Missed On Wall Street On Thursday"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231102010600"", ""headline"": ""Amgen upgraded to Buy from Hold at Truist"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231102010808"", ""headline"": ""The Amgen Inc (AMGN) Company: A Short SWOT Analysis"", ""summary"": ""Unveiling the Strengths and Challenges: A Deep Dive into Amgen Inc (AMGN) SWOT Analysis""}, {""date"": ""20231102011700"", ""headline"": ""Amgen upgraded to Buy on pipeline execution at Truist"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231102015948"", ""headline"": ""Amazon headed for rosy period, says HSBC; Roku flying: 6 big analyst picks"", ""summary"": ""Truist upgraded Amgen (NASDAQ:AMGN) to Buy from Hold with a price target of $320.00 (from $260.00), citing the biotech's commercial execution and \""ability to grow mid-cycle assets\"" to achieve record sales, \""despite underwhelming initial launches.\""""}, {""date"": ""20231102032500"", ""headline"": ""Amgen presents new data on KRYSTEXXA"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231102045700"", ""headline"": ""Roku upgraded, Amazon initiated: Wall Street's top analyst calls"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231102053100"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), IQVIA Holdings (IQV) and Argenx Se (ARGX)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231102054500"", ""headline"": ""Dow up 200 points on gains in Amgen, Walgreens Boots shares"", ""summary"": ""Buoyed by strong returns for shares of Amgen and Walgreens Boots, the Dow Jones Industrial Average is up Thursday morning. The Dow is trading 200 points...""}, {""date"": ""20231102070000"", ""headline"": ""What You Missed On Wall Street This Morning"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231102080000"", ""headline"": ""AMGEN PRESENTS NEW DATA THAT SHOW BLOOD PRESSURE DECREASES FOR ADULTS TREATED WITH KRYSTEXXA\u00ae (PEGLOTICASE)"", ""summary"": ""Amgen (NASDAQ:AMGN) today announced new data for KRYSTEXXA\u00ae (pegloticase) showing a decrease in blood pressure during treatment of adults living with chronic gout refractory to oral urate-lowering treatment \u2212 uncontrolled gout \u2212 both with and without chronic kidney disease (CKD). The data will be presented at the American Society of Nephrology Kidney Week, taking place Nov. 2-5, in Philadelphia.""}, {""date"": ""20231102082100"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Beam Therapeutics (BEAM) and Argenx Se (ARGX)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231102083200"", ""headline"": ""Concerns Over Amgen\u2019s Performance and Future Prospects: An In-Depth Sell Rating Analysis"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231102083200"", ""headline"": ""Analysts Have Conflicting Sentiments on These Healthcare Companies: Amgen (AMGN), Eli Lilly & Co (LLY) and Repligen (RGEN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231102091835"", ""headline"": ""Truist Securities Upgrades AMGEN (AMGN)"", ""summary"": """"}, {""date"": ""20231102231600"", ""headline"": ""Morgan Stanley Sticks to Its Hold Rating for Amgen (AMGN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231103123800"", ""headline"": ""Amgen Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Amgen Inc. rallied 1.23% to $269.86 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index...""}]",{}
43,2023-11-05,261.9800109863281,2023-11-12,259.5044250488281,-0.009449522229500129,D1,"[{""date"": ""20231105220200"", ""headline"": ""The doctor lowering drug prices for 1 million patients, with help from Mark Cuban, Sam Altman \u2013 and Martin Shkreli"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231106090006"", ""headline"": ""Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It"", ""summary"": ""Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.""}, {""date"": ""20231106110000"", ""headline"": ""Epidemiology and Genetics of Clonal Hematopoiesis, a Premalignant Hematopoietic Stem Cell Condition"", ""summary"": ""A comprehensive new study from deCODE genetics, a subsidiary of Amgen, published today in Nature Genetics, provides insights into the epidemiology and somatic and germline genetics of clonal hematopoiesis. Whole genome sequence data from Iceland and the UK Biobank, combined with a unique somatic mutation Barcoding strategy, was used to investigate clonal hematopoiesis at the population scale.""}, {""date"": ""20231106112812"", ""headline"": ""November Dogs Of The Dow: 3 Buyable, 4 Watchable"", ""summary"": ""Learn about the Dow Jones Industrial Average and the top-performing stocks in November. Click to see our exclusive list of dividend stocks we consider buyable now.""}, {""date"": ""20231106113800"", ""headline"": ""Amgen Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Amgen Inc. rallied 1.10% to $272.83 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...""}, {""date"": ""20231106220400"", ""headline"": ""Amgen reports data from Phase 2 study evaluating dazodalibep"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231107055300"", ""headline"": ""See How Amgen Ranks Among Analysts' Top Dow 30 Picks"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231107055500"", ""headline"": ""Video: Dow Analyst Moves: AMGN"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231107082823"", ""headline"": ""High Yield Stock Watchlist - November 2023"", ""summary"": ""The majority of the 22 stocks on my high yield watchlist for November 2023 are undervalued based on dividend yield theory. Click here for the complete list.""}, {""date"": ""20231107095008"", ""headline"": ""Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio"", ""summary"": ""Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.""}, {""date"": ""20231107113800"", ""headline"": ""Amgen Inc. stock falls Tuesday, underperforms market"", ""summary"": ""Shares of Amgen Inc. slipped 0.63% to $271.11 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...""}, {""date"": ""20231107160000"", ""headline"": ""AMGEN PRESENTS NEW DATA FROM PHASE 2 TRIAL OF DAZODALIBEP IN SJ\u00d6GREN'S SYNDROME AT ACR 2023"", ""summary"": ""Amgen (NASDAQ:AMGN) today announced new data from its Phase 2 study evaluating dazodalibep, an investigational medicine, for the treatment of Sj\u00f6gren's. These results will be featured in presentations at the American College of Rheumatology (ACR) Convergence 2023, Nov. 10-15, in San Diego. Findings from the study demonstrate that dazodalibep may improve both the systemic and symptomatic disease burden of two different patient populations.""}, {""date"": ""20231107160500"", ""headline"": ""AMGEN PRESENTS NEW RESEARCH IN EARLY PSORIATIC ARTHRITIS AT ACR 2023"", ""summary"": ""Amgen (NASDAQ:AMGN) today announced results from the global Phase 4 FOREMOST study evaluating Otezla\u00ae (apremilast) in patients with early oligoarticular psoriatic arthritis. FOREMOST is the first placebo-controlled study designed to specifically assess people with oligoarticular psoriatic arthritis with early disease duration of five or fewer years. Results will be presented at the American College of Rheumatology (ACR) Convergence 2023, Nov. 10-15 in San Diego.""}, {""date"": ""20231107222600"", ""headline"": ""Amgen initiated with a Hold at Deutsche Bank"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231108054700"", ""headline"": ""Amgen's Rare Autoimmune Disease Candidate Shows Improvement In Disease Burden In Treating Sj\u00f6gren's Syndrome"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231108075700"", ""headline"": ""CytomX Therapeutics price target raised to $3 from $2 at Wedbush"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231108110100"", ""headline"": ""Ligand Reports Third Quarter 2023 Financial Results"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231108113800"", ""headline"": ""Amgen Inc. stock rises Wednesday, outperforms market"", ""summary"": ""Shares of Amgen Inc. inched 0.79% higher to $273.26 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P...""}, {""date"": ""20231108200900"", ""headline"": ""Sen. Elizabeth Warren tells FTC she remains concerned about Amgen's Horizon deal"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231109015700"", ""headline"": ""GLOBAL BROKER RATINGS: Wells Fargo raises Adyen; HSBC likes AB InBev"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231109034940"", ""headline"": ""Top 20 Drug Companies in the US by Revenue"", ""summary"": ""In this article, we will be taking a look at the top 20 drug companies in the US by revenue. To skip our detailed analysis, you can go directly to see the Top 5 Drug Companies in the US by Revenue. Following the Covid-19 pandemic, which drastically altered the way of living, the top pharmaceutical [\u2026]""}, {""date"": ""20231109072200"", ""headline"": ""Eli Lilly declines a day after FDA nod for weight loss therapy"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231109075200"", ""headline"": ""Fortunes Can Be Made With Bristol-Myers Squibb"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231109080000"", ""headline"": ""US Senator Elizabeth Warren expresses 'disappointment' in FTC's Amgen decision"", ""summary"": ""Senator Elizabeth Warren, an antitrust hawk, expressed disappointment with the U.S. Federal Trade Commission's decision to allow pharmaceutical firm Amgen to move forward with its acquisition of Horizon Therapeutics.  Warren, a Democrat, has staunchly supported the FTC and Justice Department's tougher stance on mergers under President Joe Biden.  In a rare break with the Biden administration's antitrust enforcers, she urged them to get even tougher.""}, {""date"": ""20231109080800"", ""headline"": ""Amgen, Home Depot share losses contribute to Dow's 150-point drop"", ""summary"": ""Shares of Amgen and Home Depot are trading lower Thursday afternoon, sending the Dow Jones Industrial Average into negative territory. The Dow was most...""}, {""date"": ""20231109083606"", ""headline"": ""Deutsche Bank Initiates Coverage of AMGEN (AMGN) with Hold Recommendation"", ""summary"": """"}, {""date"": ""20231109094200"", ""headline"": ""Dow's nearly 250-point fall led by losses in shares of Amgen, Home Depot"", ""summary"": ""Shares of Amgen and Home Depot are posting losses Thursday afternoon, sending the Dow Jones Industrial Average into negative territory. Shares of Amgen and...""}, {""date"": ""20231109113800"", ""headline"": ""Amgen Inc. stock underperforms Thursday when compared to competitors"", ""summary"": ""Shares of Amgen Inc. shed 3.37% to $264.06 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20231110015300"", ""headline"": ""Mirati lung cancer therapy endorsed in EU"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231110073800"", ""headline"": ""12 Dogs of the Dow Dividend Stocks to Buy"", ""summary"": ""In this article, we discuss 12 Dogs of the Dow dividend stocks to buy. You can skip our detailed analysis of the dogs of the Dow strategy and its returns over the years, and go directly to read 5 Dogs of the Dow Dividend Stocks to Buy. Many investors who prioritize dividends find dividend yields [\u2026]""}, {""date"": ""20231110090000"", ""headline"": ""AMGEN PRESENTS NEW CARDIOVASCULAR RESEARCH AT AHA 2023"", ""summary"": ""Amgen (NASDAQ:AMGN) today announced new data reinforcing the safety and efficacy of Repatha\u00ae (evolocumab) from the FOURIER Open Label Extension (OLE) [FOURIER-OLE] trial at the American Heart Association (AHA) Scientific Sessions 2023 in Philadelphia. These presentations will focus on the reduction of a known cardiovascular disease (CVD) risk factor, LDL \""bad\"" cholesterol (LDL-C). Amgen will also present new research from the Phase 2 OCEAN(a)-DOSE study of its investigational small interfering R""}, {""date"": ""20231110101500"", ""headline"": ""2 Top Biotech Stocks to Buy Right Now"", ""summary"": ""It's been a rough year for the biotech industry, which as a whole has substantially lagged the broader market.  Two worth a closer look today are Amgen (NASDAQ: AMGN) and Moderna (NASDAQ: MRNA) whose prospects really don't look as bad as their year-to-date performances suggest.  At current levels, both Amgen and Moderna are worth investing in now.""}, {""date"": ""20231110113800"", ""headline"": ""Amgen Inc. stock rises Friday, still underperforms market"", ""summary"": ""Shares of Amgen Inc. rose 1.23% to $267.31 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20231111040000"", ""headline"": ""Why You Should Aim For $2 Million For Retirement"", ""summary"": ""Retirement goals should be set based on individual situations and factors like your pre-retirement earnings. Explore more details here.""}, {""date"": ""20231111070535"", ""headline"": ""Amgen Inc. (NASDAQ:AMGN) Looks Like A Good Stock, And It's Going Ex-Dividend Soon"", ""summary"": ""Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Amgen Inc...""}, {""date"": ""20231111144055"", ""headline"": ""Dividend Champion, Contender, And Challenger Highlights: Week Of November 12"", ""summary"": ""A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Read more to see the November 12 weekly update.""}, {""date"": ""20231111171424"", ""headline"": ""3.2%-Yielding Amgen's Realistic Path To >11% Annual Returns"", ""summary"": ""Amgen completes acquisition of Horizon Therapeutics, boosting long-term growth potential. Read why we have a buy rating on AMGN stock.""}, {""date"": ""20231112060500"", ""headline"": ""Eli Lilly expected to add $4.1B U.S. sales from new weight loss drug"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
44,2023-11-12,259.5044250488281,2023-11-19,259.6662902832031,0.0006237474923387332,U1,"[{""date"": ""20231112060500"", ""headline"": ""Eli Lilly expected to add $4.1B U.S. sales from new weight loss drug"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231112230400"", ""headline"": ""PRIMECAP Management Adjusts Portfolio, Notably Trims Eli Lilly Stake"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231112231955"", ""headline"": ""OUSA: Attractive Quality, Average Performance"", ""summary"": ""OUSA ETF holds 100 dividend stocks selected and weighted based on profitability, dividend quality, leverage and volatility. Read why I'm neutral on the fund.""}, {""date"": ""20231113113800"", ""headline"": ""Amgen Inc. stock underperforms Monday when compared to competitors"", ""summary"": ""Shares of Amgen Inc. slipped 0.23% to $266.69 Monday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...""}, {""date"": ""20231113130601"", ""headline"": ""6 intriguing stocks investors should consider: Piper Sandler"", ""summary"": ""The market has slightly rebounded, with some investors excited for a possible Santa Claus rally to close out the year. Piper Sandler's technical research team announced six stocks that are currently looking attractive for investor portfolios: Amazon (AMZN), Amgen Inc. (AMGN), Coterra Energy (CTRA), Lululemon (LULU), Assurant (AIZ), and Palo Alto Networks (PANW). Jason Glazer, Piper Sandler & Co. Managing Director and Head of Product Management, joins Yahoo Finance to break down the company's picks, how they arrived there, and give insight into the chosen stocks. \""[Lululemon] stands out because it has both high earnings growth and earnings expectations and if you go into the business they have pretty high margins with about 45% of sales coming from company-owned sales and 45% of sales coming through the e-commerce channel,\"" Glazer explains. \""They're tremendous at product innovation, they keep full-price selling, unlike a lot of the discounting you see in the retail industry, and they also have some tremendous growth opportunities in China.\"" For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.""}, {""date"": ""20231113142229"", ""headline"": ""13 Dividend Giants with Lowest Short Interest"", ""summary"": ""In this article, we discuss 13 dividend giants with the lowest short interest. You can skip our detailed analysis of dividend stocks and their previous performance, and go directly to read 5 Dividend Giants with Lowest Short Interest. While the financial world is typically viewed as serious and analytical, the art of short selling adds [\u2026]""}, {""date"": ""20231113190505"", ""headline"": ""13 Cheap Blue Chip Stocks To Buy"", ""summary"": ""In this piece, we will take a look at the 13 cheap blue chip stocks to buy. To skip our overview of the blue chip sector and the latest news about the stock market, take a look at the 5 Cheap Blue Chip Stocks To Buy. Within the American stock market, the Dow Jones Industrial [\u2026]""}, {""date"": ""20231114014650"", ""headline"": ""Amgen Is Still A Hold, But Should Be On Your Watchlist"", ""summary"": ""Amgen is a resilient healthcare company that tends to perform well in challenging business environments. See why I think AMGN stock is still a hold.""}, {""date"": ""20231114042100"", ""headline"": ""Ex-Dividend Reminder: Amgen, Royalty Pharma and Phillips Edison"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231114063100"", ""headline"": ""Eli Lilly (NYSE:LLY) Slips despite Good News on Heart Drug"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231114113800"", ""headline"": ""Amgen Inc. stock rises Tuesday, still underperforms market"", ""summary"": ""Shares of Amgen Inc. rose 1.25% to $270.02 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20231114160734"", ""headline"": ""Amgen: Buy In Stable Fundamental And Technical Price Growth"", ""summary"": ""Amgen's Q3 2023 financial performance showed increased total revenues and product sales, driven by volume growth and strong international markets. Click here to read my analysis.""}, {""date"": ""20231115000300"", ""headline"": ""Invest with Confidence: Intrinsic Value Unveiled of Amgen Inc"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231115034500"", ""headline"": ""O'Keefe Stevens Advisory Q3 2023 Update"", ""summary"": ""At the end of Q3 2023, O'Keefe Stevens Advisory's top 5 holdings represented ~27% of assets, down from 35% at the end of Q2. Click here to read the full fund letter. ""}, {""date"": ""20231115044900"", ""headline"": ""1 in 25 carries a genotype that is associated with a shortened lifespan"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231115050611"", ""headline"": ""Amgen Inc's Dividend Analysis"", ""summary"": ""Amgen Inc(NASDAQ:AMGN) recently announced a dividend of $2.13 per share, payable on 2023-12-08, with the ex-dividend date set for 2023-11-16.  As investors look forward to this upcoming payment, the spotlight also shines on the company's dividend history, yield, and growth rates.  Using the data from GuruFocus, let's look into Amgen Inc's dividend performance and assess its sustainability.""}, {""date"": ""20231115063900"", ""headline"": ""10 Health Care Stocks Whale Activity In Today's Session"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231115113800"", ""headline"": ""Amgen Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Amgen Inc. rose 1.11% to $273.03 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...""}, {""date"": ""20231116011200"", ""headline"": ""Homology Medicines, Q32 Bio enter all-stock merger agreement"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231116030000"", ""headline"": ""Big Pharma scrambles to feed demand for weight-loss treatments amid rising US obesity rates"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231116062200"", ""headline"": ""Amgen Inc(AMGN) 2022 CEO Robert A. Bradway's shareholder letter: A Year of Strong Performance ..."", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231116063200"", ""headline"": ""Homology Medicines slumps after merger deal with Q32 Bio"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231116113800"", ""headline"": ""Amgen Inc. stock falls Thursday, underperforms market"", ""summary"": ""Shares of Amgen Inc. slipped 0.70% to $269.00 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20231116143601"", ""headline"": ""Amgen : LUMAKRAS\u00ae (sotorasib) Dose Comparison Study Results"", ""summary"": ""LUMAKRAS\u00ae Dose Comparison Study Results Today, during an ESMO Plenary Virtual Session, Amgen presented data from the LUMAKRAS\u00ae 960 mg versus 240 mg dose comparison study in...""}, {""date"": ""20231117090005"", ""headline"": ""Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know"", ""summary"": ""Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.""}, {""date"": ""20231117113800"", ""headline"": ""Amgen Inc. stock falls Friday, underperforms market"", ""summary"": ""Shares of Amgen Inc. shed 1.34% to $265.39 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20231119053901"", ""headline"": ""18 Best-Performing Dow Stocks in 2023"", ""summary"": ""In this article, we will take a look at the 18 best-performing Dow stocks in 2023. To see more such companies, go directly to 5 Best-Performing Dow Stocks in 2023. The economy and stock markets have defied almost every prediction and estimate in 2023. When the year started there was almost a consensus among notable [\u2026]""}, {""date"": ""20231119060200"", ""headline"": ""M&A, GLP-1s to dominate healthcare themes in 2024 as COVID fades: survey"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231119163759"", ""headline"": ""Tracking George Soros' 13F Portfolio - Q3 2023 Update"", ""summary"": ""George Soros' 13F portfolio value increased by 10% to $7.05B. Click here to read more about Soros Fund Management's holdings and trades for Q3 2023.""}]",{}
45,2023-11-19,259.6662902832031,2023-11-26,259.7347717285156,0.00026372866973911613,U1,"[{""date"": ""20231119053901"", ""headline"": ""18 Best-Performing Dow Stocks in 2023"", ""summary"": ""In this article, we will take a look at the 18 best-performing Dow stocks in 2023. To see more such companies, go directly to 5 Best-Performing Dow Stocks in 2023. The economy and stock markets have defied almost every prediction and estimate in 2023. When the year started there was almost a consensus among notable [\u2026]""}, {""date"": ""20231119060200"", ""headline"": ""M&A, GLP-1s to dominate healthcare themes in 2024 as COVID fades: survey"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231119163759"", ""headline"": ""Tracking George Soros' 13F Portfolio - Q3 2023 Update"", ""summary"": ""George Soros' 13F portfolio value increased by 10% to $7.05B. Click here to read more about Soros Fund Management's holdings and trades for Q3 2023.""}, {""date"": ""20231119204500"", ""headline"": ""Fly Insider: Air Products, Amgen among  this week's notable insider trades"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231119212600"", ""headline"": ""Bernard Horn's Polaris Global Value Fund 3rd-Quarter Letter"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231119232800"", ""headline"": ""Rep. James Comer probes FTC conduct in Amgen's takeover of Horizon Therapeutics"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231120002900"", ""headline"": ""Harpoon Therapeutics initiated with an Outperform at TD Cowen"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231120065224"", ""headline"": ""20 Most Valuable Healthcare Companies in the World"", ""summary"": ""In this article, we will look into the 20 most valuable healthcare companies in the world. If you want to skip our detailed analysis, you can go directly to the 5 Most Valuable Healthcare Companies in the World. Healthcare Services Industry: A Market Analysis According to a report by Verified Market Research, the global healthcare [\u2026]""}, {""date"": ""20231120113800"", ""headline"": ""Amgen Inc. stock underperforms Monday when compared to competitors"", ""summary"": ""Shares of Amgen Inc. dropped 0.02% to $265.35 Monday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...""}, {""date"": ""20231120190148"", ""headline"": ""Billionaire Steven Cohen\u2019s Top High Dividend Stock Picks"", ""summary"": ""In this article, we discuss billionaire Steve Cohen\u2019s top high-dividend stock picks. You can skip our detailed analysis of Point72 Asset Management\u2019s holding and recent developments, and go directly to read Billionaire Steven Cohen\u2019s Top 5 High Dividend Stock Picks. Steve Cohen is a prominent figure in the world of finance and investing, known for [\u2026]""}, {""date"": ""20231121030500"", ""headline"": ""Munger And Buffett Say Invest $100,000 For Financial Freedom: Consider SCHD"", ""summary"": ""Charlie Munger has emphasized the importance of investing $100,000. See why SCHD ETF is a strong investment option for reaching financial freedom.""}, {""date"": ""20231121065300"", ""headline"": ""AbbVie Vs. Amgen: How Peter Lynch Picks Dividend Stocks"", ""summary"": ""This article examines two healthcare stalwarts, AbbVie (ABBV) and Amgen (AMGN) through the lens of Lynch's approach. Check out which stock I prefer.""}, {""date"": ""20231121083210"", ""headline"": ""Bristol-Myers Squibb: A Tough But Cheap Spot"", ""summary"": ""Learn about the challenges facing Bristol-Myers Squibb as it deals with loss of exclusivity, growth concerns, and other issues. Click here for more on BMY stock.""}, {""date"": ""20231121113800"", ""headline"": ""Amgen Inc. stock falls Tuesday, underperforms market"", ""summary"": ""Shares of Amgen Inc. dropped 0.95% to $262.82 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20231121225500"", ""headline"": ""Matrix Asset Advisors Q3 2023 Capital Markets Commentary And Quarterly Report"", ""summary"": ""For Q3 2023, Matrix\u00e2\u0080\u0099s LCV and MDI portfolios were down modestly, and bond returns mostly flat or down. Click here to read the full fund letter.""}, {""date"": ""20231122040000"", ""headline"": ""Merck: Keytruda Patent Expiry Nears With Replacement Yet To Be Found"", ""summary"": ""For now, Merck's prospects have somewhat dimmed, with management engaging on expensive partnerships to boost its pipelines. Learn why we rate MRK stock a hold.""}, {""date"": ""20231122051700"", ""headline"": ""P/E Ratio Insights for Amgen"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231122113800"", ""headline"": ""Amgen Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Shares of Amgen Inc. inched 0.67% higher to $264.59 Wednesday, on what proved to be an all-around great trading session for the stock market, with the S&P...""}, {""date"": ""20231122160000"", ""headline"": ""AMGEN TO PRESENT AT THE EVERCORE ISI HEALTHCONX CONFERENCE"", ""summary"": ""Amgen (NASDAQ:AMGN) will present at the Evercore ISI HealthCONx Conference at 9:10 a.m. EST on Wednesday, Nov. 29, 2023. Peter H. Griffith, executive vice president and chief financial officer at Amgen, and Paul Burton, senior vice president and chief medical officer at Amgen will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.""}, {""date"": ""20231123213000"", ""headline"": ""Mario Gabelli's Gabelli Asset Fund 3rd-Quarter Commentary"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231123223900"", ""headline"": ""Amgen Inc. stock outperforms market on strong trading day"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231124005300"", ""headline"": ""Innovent marks China's first regulatory review of a KRAS G12C inhibitor"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231124050200"", ""headline"": ""Investigating Amgen's Standing In Biotechnology Industry Compared To Competitors"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231126065103"", ""headline"": ""15 Best Drug Stocks To Invest In"", ""summary"": ""In this article, we discuss the 15 best drug stocks to invest in. You can skip our detailed analysis of the drug and pharmaceutical sector and its outlook this year, and go directly to read the 5 Best Drug Stocks To Invest In. Healthcare expands on the defensive concept, encompassing a myriad of companies. This [\u2026]""}]",{}
46,2023-11-26,259.7347717285156,2023-12-03,266.5740051269531,0.02633160494038944,U3,"[{""date"": ""20231126065103"", ""headline"": ""15 Best Drug Stocks To Invest In"", ""summary"": ""In this article, we discuss the 15 best drug stocks to invest in. You can skip our detailed analysis of the drug and pharmaceutical sector and its outlook this year, and go directly to read the 5 Best Drug Stocks To Invest In. Healthcare expands on the defensive concept, encompassing a myriad of companies. This [\u2026]""}, {""date"": ""20231127054410"", ""headline"": ""Mastercard, Pfizer Among 18 Companies To Announce Dividend Increases In December"", ""summary"": ""2H of November saw announcements of annual dividend increases from 9 companies. 16 other companies will announce annual increases before Christmas. Read more here.""}, {""date"": ""20231127070300"", ""headline"": ""Novo falls as long-time investor cuts stake on weight loss hype"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231127113800"", ""headline"": ""Amgen Inc. stock falls Monday, underperforms market"", ""summary"": ""Shares of Amgen Inc. dropped 0.45% to $264.27 Monday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20231127203500"", ""headline"": ""Amazon Web Services, Amgen to work on generative AI solutions to advance therapies"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231127213800"", ""headline"": ""Amgen (NASDAQ:AMGN) Gains with New AWS Partnership"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231127221500"", ""headline"": ""Amgen (NASDAQ:AMGN) Gains on New AWS Partnership"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231128012000"", ""headline"": ""Amgen receives Orphan Drug Designation for treatment of biliary tract cancers"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231128090000"", ""headline"": ""1 Spectacular Dividend Stock Every Investor Should Consider"", ""summary"": ""Dividend stocks are versatile investments that can serve different purposes in a portfolio.  Others use them to boost their portfolio's performance by reinvesting the dividends to compound their returns over time.  Here is a brief overview of one blue-chip dividend stock that has successfully served both roles (income generation and above-average capital appreciation) over the past 12 years and that also appears more than capable of continuing this tradition for the foreseeable future.""}, {""date"": ""20231128090005"", ""headline"": ""Is Trending Stock Amgen Inc. (AMGN) a Buy Now?"", ""summary"": ""Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.""}, {""date"": ""20231128103617"", ""headline"": ""This Stock Hasn't Split Since 1999 \u2014 $1,000 Invested Then Would Be Worth A Boatload Today"", ""summary"": ""When investing in the stock market, a history of strong returns should be high on your priority list. Combine this with a positive outlook on the future, and you may have a winner to add to your portfolio. Amgen Inc., an American multinational biopharmaceutical company, fits this mold. The company has a 10-year annualized total return of 13.69% through the end of 2022. And if that's not enough to pique your interest, consider this: It pays out billions of dollars in dividends to investors every""}, {""date"": ""20231128133441"", ""headline"": ""AWS expands big pharma partnerships in manufacturing, AI, and R&D"", ""summary"": ""Pfizer and Amazon Web Services are just another example of how artificial intelligence is working in the background in healthcare.""}, {""date"": ""20231129000400"", ""headline"": ""The Art of Valuation: Discovering Amgen Inc's Intrinsic Value"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231129022200"", ""headline"": ""Amazon cloud conference impresses, Rosenblatt sees AI boost"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231129025700"", ""headline"": ""Amazon cloud conference impresses, Wall Street sees AI boost"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231129062526"", ""headline"": ""Why I Made Big Changes To My Dividend Growth Portfolio"", ""summary"": ""How to make significant changes to your portfolio, for when buying a new house and selling stocks for cash? Click here to read about my strategy.""}, {""date"": ""20231129070600"", ""headline"": ""Analyst Ratings for Amgen"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231129074805"", ""headline"": ""Amgen Inc. (AMGN) Presents at 6th Annual Evercore ISI HealthCONx Conference (Transcript)"", ""summary"": ""Amgen Inc. (NASDAQ:NASDAQ:AMGN) 6th Annual Evercore ISI HealthCONx Conference November 29, 2023 9:10 AM ETCompany ParticipantsPeter Griffith - EVP and...""}, {""date"": ""20231129145200"", ""headline"": ""Top Stock Reports for McDonald's, Amgen & NextEra Energy"", ""summary"": ""Today's Research Daily features new research reports on 16 major stocks, including McDonald's Corporation (MCD), Amgen Inc. (AMGN) and NextEra Energy, Inc. (NEE).""}, {""date"": ""20231130060200"", ""headline"": ""Looking Into Amgen's Recent Short Interest"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231130084400"", ""headline"": ""Amazon (AMZN) Teams Up With Amgen, Expands Customer Base"", ""summary"": ""Amazon's (AMZN) AWS gets selected by Amgen. This highlights the efficiency and reliability of AWS' innovative cloud products and services.""}, {""date"": ""20231130101600"", ""headline"": ""The Zacks Analyst Blog Highlights McDonald's, Amgen, NextEra Energy, General Mills and Take-Two Interactive Software"", ""summary"": ""McDonald's, Amgen, NextEra Energy, General Mills and Take-Two Interactive Software are included in this Analyst Blog.""}, {""date"": ""20231130113055"", ""headline"": ""Amgen (AMGN) Up 2.2% Since Last Earnings Report: Can It Continue?"", ""summary"": ""Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.""}, {""date"": ""20231130113800"", ""headline"": ""Amgen Inc. stock underperforms Thursday when compared to competitors despite daily gains"", ""summary"": ""Shares of Amgen Inc. rallied 1.14% to $269.64 Thursday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...""}, {""date"": ""20231201011600"", ""headline"": ""Pfizer pulls back from twice-daily regime of weight-loss drug candidate"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231201040008"", ""headline"": ""Arrowhead Pharmaceuticals: Balance Sheet Concern Needs To Be Addressed"", ""summary"": ""Arrowhead Pharmaceuticals stock drops on balance sheet concerns following fiscal Q3 results. Read why I think positive preclinical results offer hope for ARWR.""}, {""date"": ""20231201043000"", ""headline"": ""Worried About a Weight-Loss Stock Bubble? Here Are Some Alternatives."", ""summary"": ""Eli Lilly and Novo Nordisk, riding the wave of enthusiasm for obesity meds, are seeing their stock prices soar. But behind them are coming new therapies from companies for investors that are drawn to the size of the obesity market but put off by the valuations.""}, {""date"": ""20231201065400"", ""headline"": ""Pfizer hits new 52-week low after weight loss setback"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231201084749"", ""headline"": ""\u2018From Hype to Clinical\u2018: Cowen Suggests 2 AI Healthcare Stocks to Consider"", ""summary"": ""Just over a year ago, AI technology burst into our collective consciousness with the launch of ChatGPT. Generative AI has quickly shown a high potential to change the way we communicate with the digital world \u2013 and it can bring a similar potential to other fields, from automobiles to healthcare. The magnitude of AI\u2019s potential is clear from the estimates: tech experts are predicting that AI\u2019s application to the healthcare market could exceed $100 billion before 2030. The gains will come on the h""}, {""date"": ""20231201095700"", ""headline"": ""Weight-Loss Stocks Are Getting Pricey. Time to Worry About a Bubble?"", ""summary"": ""Eli Lilly and Novo Nordisk, riding the wave of enthusiasm for obesity meds, are seeing their stock prices soar. But behind them are coming new therapies from companies for investors that are drawn to the size of the obesity market but put off by the valuations.""}, {""date"": ""20231201113800"", ""headline"": ""Amgen Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Amgen Inc. advanced 1.04% to $272.45 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...""}, {""date"": ""20231203021023"", ""headline"": ""Dividend Champion, Contender, And Challenger Highlights: Week Of December 3"", ""summary"": ""A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Read more to see the update for the week of December 3.""}, {""date"": ""20231203060400"", ""headline"": ""Biotechs post record gains in November amid improving outlook"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231203161400"", ""headline"": ""Obesity Drugs Have Multi-Billion-Dollar Market Potential, Says Oppenheimer \u2014 Here Are 2 Stocks to Take Advantage"", ""summary"": ""A key to success in the stock market is a touch of foresight. Not quite precognition, but an ability to spot and put together clues and trends, to discern the \u2018next big thing\u2019 before it hits. This is true in every stock sector, but today we\u2019ll focus on biotech. The biotech firms have famously high product lead times, paired with equally high overhead expenses; it\u2019s a combination that would make them unlikely investments, except that when a drug is approved, it can turn into a blockbuster. Succes""}]",{}
47,2023-12-03,266.5740051269531,2023-12-10,263.3158264160156,-0.012222417221010806,D2,"[{""date"": ""20231203021023"", ""headline"": ""Dividend Champion, Contender, And Challenger Highlights: Week Of December 3"", ""summary"": ""A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Read more to see the update for the week of December 3.""}, {""date"": ""20231203060400"", ""headline"": ""Biotechs post record gains in November amid improving outlook"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231203161400"", ""headline"": ""Obesity Drugs Have Multi-Billion-Dollar Market Potential, Says Oppenheimer \u2014 Here Are 2 Stocks to Take Advantage"", ""summary"": ""A key to success in the stock market is a touch of foresight. Not quite precognition, but an ability to spot and put together clues and trends, to discern the \u2018next big thing\u2019 before it hits. This is true in every stock sector, but today we\u2019ll focus on biotech. The biotech firms have famously high product lead times, paired with equally high overhead expenses; it\u2019s a combination that would make them unlikely investments, except that when a drug is approved, it can turn into a blockbuster. Succes""}, {""date"": ""20231203235100"", ""headline"": ""Roche ventures into weight-loss drug market with $2.7B buyout of Carmot"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231204025109"", ""headline"": ""December Dogs Of The Dow: 3 Buyable, 5 Watchable"", ""summary"": ""Some of these Dow Industrials are too pricey and reveals only skinny dividends. Read here about 3 of the 5 lowest-priced Dogs of the Dow which are ready to buy.""}, {""date"": ""20231204055900"", ""headline"": ""Viking Therapeutics rises on Roche acquiring peer Carmot"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231204113800"", ""headline"": ""Amgen Inc. stock rises Monday, outperforms market"", ""summary"": ""Shares of Amgen Inc. inched 0.03% higher to $272.54 Monday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500...""}, {""date"": ""20231204141402"", ""headline"": ""Amgen : Understanding Patient Communities Is Vital for Clinical Trial Education"", ""summary"": ""Hispanic communities in the US face health disparities across a wide range of conditions, from cancer and heart disease to obesity and diabetes. One potential root of these disparities...""}, {""date"": ""20231204210342"", ""headline"": ""Dominate the Dow for safe returns, fat dividends with our AI-driven ProPicks"", ""summary"": ""Amid the 30 companies that compose the Dow Jones Industrial Average, 'Dominate the Dow' pinpoints the top 10 \""blue chip\"" stocks that offer the best buy proposition at the moment.""}, {""date"": ""20231205113800"", ""headline"": ""Amgen Inc. stock underperforms Tuesday when compared to competitors"", ""summary"": ""Shares of Amgen Inc. sank 0.61% to $270.87 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20231206034700"", ""headline"": ""P/E Ratio Insights for Amgen"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231206052200"", ""headline"": ""Top stocks with highest hedge fund + mutual fund positions, according to GS"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231206054000"", ""headline"": ""Top 30 stocks with highest hedge fund + mutual fund short positions \u2013 GS"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231206060900"", ""headline"": ""30 Stocks shunned by hedge and mutual funds - GS"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231206113800"", ""headline"": ""Amgen Inc. stock falls Wednesday, underperforms market"", ""summary"": ""Shares of Amgen Inc. sank 0.56% to $269.35 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20231206175015"", ""headline"": ""Amgen (AMGN) Registers a Bigger Fall Than the Market: Important Facts to Note"", ""summary"": ""In the latest trading session, Amgen (AMGN) closed at $269.35, marking a -0.56% move from the previous day.""}, {""date"": ""20231206180903"", ""headline"": ""Amgen: Relative Valuation Remains Unattractive"", ""summary"": ""A closer look at the leader in the global osteoporosis treatment market""}, {""date"": ""20231207060058"", ""headline"": ""Amgen (NASDAQ:AMGN) shareholders have earned a 9.8% CAGR over the last five years"", ""summary"": ""If you buy and hold a stock for many years, you'd hope to be making a profit. Furthermore, you'd generally like to see...""}, {""date"": ""20231207113800"", ""headline"": ""Amgen Inc. stock rises Thursday, still underperforms market"", ""summary"": ""Shares of Amgen Inc. inched 0.73% higher to $271.31 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P...""}, {""date"": ""20231207185714"", ""headline"": ""MoonLake Immunotherapeutics: Poised For Acquisition"", ""summary"": ""MoonLake, a clinical-stage biopharmaceutical company, is gaining attention with its promising nanobody-based therapies for inflammatory diseases. Read more here.""}, {""date"": ""20231207210300"", ""headline"": ""Catalyst Watch: Intel's AI event, Oracle earnings and CAVA IPO lockup expiration"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231207233100"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and Edwards Lifesciences (EW)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231208053300"", ""headline"": ""Like Dividends? You Should Check Out This Wealth-Creating Income Investment"", ""summary"": ""The Schwab U.S. Dividend Equity ETF focuses on stocks that have historically delivered market-beating total returns.""}, {""date"": ""20231208090000"", ""headline"": ""AMGEN HIGHLIGHTS HEMATOLOGY PORTFOLIO AT ASH 2023"", ""summary"": ""Amgen (NASDAQ:AMGN) today announced the presentation of new data from its blood cancer portfolio and pipeline at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place from Dec. 9-12 in San Diego.""}, {""date"": ""20231208113800"", ""headline"": ""Amgen Inc. stock underperforms Friday when compared to competitors"", ""summary"": ""Shares of Amgen Inc. shed 0.81% to $269.12 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20231209054414"", ""headline"": ""Better Dividend ETF For December 2023: SCHD Or JEPI?"", ""summary"": ""Discover the power of dividend investing with popular ETFs SCHD and JEPI.""}, {""date"": ""20231209193938"", ""headline"": ""15 Least Competitive Medical Specialties in America"", ""summary"": ""In this article, we will look at the 15 least competitive medical specialities in America. We have also discussed the state of the healthcare industry in the US. If you want to skip our detailed analysis, head straight to the 5 Least Competitive Medical Specialities in America. Choosing a medical speciality involves a combination of [\u2026]""}, {""date"": ""20231210040000"", ""headline"": ""BST: High Income And Decent Growth, Can We Ask More?"", ""summary"": ""For nine years of its existence, BST has offered nearly 14% of annualized total returns. Check out our analysis of BST CEF and our recommendation.""}, {""date"": ""20231210130746"", ""headline"": ""12 Dow Stocks Billionaires Like The Most"", ""summary"": ""In this piece, we will take a look at the 12 Dow stocks that billionaires like the most. If you don\u2019t want to learn more about the Dow Jones Industrial Average (DJIA), its history, and recent performance, then skip ahead to 5 Dow Stocks Billionaires Like The Most. In its current form today, the Dow [\u2026]""}, {""date"": ""20231210160000"", ""headline"": ""INSIGHT-No global carbon price? Some companies set their own"", ""summary"": ""A growing list of global companies are setting a price or charging themselves for each metric ton of their carbon emissions, looking to shape their investments and business for future pollution taxes or other new climate rules.  Their prices are all over the place, from less than $1 per metric ton of carbon emissions to $1,600, the most of any company worldwide, set by California drugmaker Amgen.""}, {""date"": ""20231210160456"", ""headline"": ""No global carbon price? Some companies set their own"", ""summary"": ""BOSTON/DUBAI/SAN FRANCISCO (Reuters) -A growing list of global companies are setting a price or charging themselves for each metric ton of their carbon emissions, looking to shape their investments and business for future pollution taxes or other new climate rules.  Their prices are all over the place, from less than $1 per metric ton of carbon emissions to $1,600, the most of any company worldwide, set by California drugmaker Amgen.  Regulators, too, have offered a range of prices, including the Biden administration's \""social cost\"" of carbon, around $200, and a suggestion from the International Monetary Fund that it should be at least $85 by 2030.""}]",{}
48,2023-12-10,263.3158264160156,2023-12-17,269.50933837890625,0.023521229419402268,U3,"[{""date"": ""20231209193938"", ""headline"": ""15 Least Competitive Medical Specialties in America"", ""summary"": ""In this article, we will look at the 15 least competitive medical specialities in America. We have also discussed the state of the healthcare industry in the US. If you want to skip our detailed analysis, head straight to the 5 Least Competitive Medical Specialities in America. Choosing a medical speciality involves a combination of [\u2026]""}, {""date"": ""20231210040000"", ""headline"": ""BST: High Income And Decent Growth, Can We Ask More?"", ""summary"": ""For nine years of its existence, BST has offered nearly 14% of annualized total returns. Check out our analysis of BST CEF and our recommendation.""}, {""date"": ""20231210130746"", ""headline"": ""12 Dow Stocks Billionaires Like The Most"", ""summary"": ""In this piece, we will take a look at the 12 Dow stocks that billionaires like the most. If you don\u2019t want to learn more about the Dow Jones Industrial Average (DJIA), its history, and recent performance, then skip ahead to 5 Dow Stocks Billionaires Like The Most. In its current form today, the Dow [\u2026]""}, {""date"": ""20231210160456"", ""headline"": ""No global carbon price? Some companies set their own"", ""summary"": ""BOSTON/DUBAI/SAN FRANCISCO (Reuters) -A growing list of global companies are setting a price or charging themselves for each metric ton of their carbon emissions, looking to shape their investments and business for future pollution taxes or other new climate rules.  Their prices are all over the place, from less than $1 per metric ton of carbon emissions to $1,600, the most of any company worldwide, set by California drugmaker Amgen.  Regulators, too, have offered a range of prices, including the Biden administration's \""social cost\"" of carbon, around $200, and a suggestion from the International Monetary Fund that it should be at least $85 by 2030.""}, {""date"": ""20231211045628"", ""headline"": ""AMGEN HIGHLIGHTS HEMATOLOGY PORTFOLIO AT ASH 2023"", ""summary"": ""THOUSAND OAKS - Amgen today announced the presentation of new data from its blood cancer portfolio and pipeline at the 65th American Society of Hematology Annual Meeting and Exposition, taking...""}, {""date"": ""20231211050500"", ""headline"": ""Insights Into Amgen's Performance Versus Peers In Biotechnology Sector"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231211080013"", ""headline"": ""Here's Why We Think Amgen (NASDAQ:AMGN) Might Deserve Your Attention Today"", ""summary"": ""For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...""}, {""date"": ""20231211090007"", ""headline"": ""Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock"", ""summary"": ""Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.""}, {""date"": ""20231211094007"", ""headline"": ""Here's Why Amgen (AMGN) is a Strong Value Stock"", ""summary"": ""The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.""}, {""date"": ""20231211101800"", ""headline"": ""Humira leads ICER\u2019s latest list of \u2018unsupported\u2019 price hikes"", ""summary"": ""AbbVie\u2019s blockbuster medicine topped a list of\u00a0treatments that, combined, elevated U.S. healthcare spending by $1.3 billion in 2022, according to the price watchdog\u2019s latest yearly report.""}, {""date"": ""20231211153911"", ""headline"": ""INSIGHT-No global carbon price? Some companies set their own"", ""summary"": ""A growing list of global companies are setting a price or charging themselves for each metric ton of their carbon emissions, looking to shape their investments and business for future pollution taxes or other new climate rules.  Their prices are all over the place, from less than $1 per metric ton of carbon emissions to $1,600, the most of any company worldwide, set by California drugmaker Amgen.""}, {""date"": ""20231211220200"", ""headline"": ""Amgen raises dividend to $2.25 from $2.13"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231211221300"", ""headline"": ""Amgen raises quarterly dividend by 5.6% to  $2.25/share"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231211234200"", ""headline"": ""RBC Capital gets more bullish on Amgen, upgrades shares"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231212012100"", ""headline"": ""Pfizer to close Seagen buyout this week as regulatory reviews complete"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231212014900"", ""headline"": ""Amgen price target lowered by $10 at Morgan Stanley, here's why"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231212020400"", ""headline"": ""PVH To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesday"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231212023000"", ""headline"": ""Amgen just upgraded at RBC Capital, here's why"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231212042300"", ""headline"": ""Zillow upgraded, Airbnb downgraded: Wall Street's top analyst calls"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231212055500"", ""headline"": ""Amgen upgraded at RBC on catalyst setup and growth drivers"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231212101319"", ""headline"": ""US STOCKS-Wall St slips as investors assess November inflation data"", ""summary"": ""Wall Street's main indexes slipped on Tuesday following inflation data that was in line with estimates ahead of the U.S. Federal Reserve's policy decision later in the week, while losses in energy stocks also weighed.  Consumer Price Index (CPI) rose 3.1% on an annual basis in line with estimates from economists polled by Reuters.""}, {""date"": ""20231212110900"", ""headline"": ""Amgen raises dividend to $2.25 a share"", ""summary"": ""Amgen Inc. said late Tuesday its board has authorized a dividend of $2.25 a share, up from $2.13 a share. That\u2019s the 12th straight year that Amgen has...""}, {""date"": ""20231212112705"", ""headline"": ""Amgen Raises Dividend 5.6% To $2.25 A Share"", ""summary"": ""By Ben Glickman Amgen is raising its dividend by 5.6%, marking the company's 12th consecutive year with an increased payout to shareholders. The Thousand Oaks, Calif.-based pharmaceutical...""}, {""date"": ""20231212160000"", ""headline"": ""AMGEN ANNOUNCES 2024 FIRST QUARTER DIVIDEND INCREASE TO $2.25 PER SHARE"", ""summary"": ""Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.25 per share dividend for the first quarter of 2024. This is the 12th consecutive year that Amgen has increased its dividend and comes as the Company continues to invest in innovation and deleverage its balance sheet. The dividend will be paid on March 7, 2024, to all stockholders of record as of the close of business on February 16, 2024.""}, {""date"": ""20231212172310"", ""headline"": ""RBC Capital Upgrades AMGEN (AMGN)"", ""summary"": """"}, {""date"": ""20231212175014"", ""headline"": ""Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know"", ""summary"": ""Amgen (AMGN) reachead $273.99 at the closing of the latest trading day, reflecting a +0.68% change compared to its last close.""}, {""date"": ""20231212220200"", ""headline"": ""Amgen granted Priority Review by FDA for BLA for tarlatamab"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231212224800"", ""headline"": ""Amgen gets FDA priority review for small cell lung cancer drug"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231213010403"", ""headline"": ""Amgen : increase in quarterly dividend"", ""summary"": ""Amgen announced Tuesday evening that its Board of Directors has decided to increase its quarterly dividend to $2.25 per share for the first quarter of 2024. The dividend will be payable on March 7 to...""}, {""date"": ""20231213101500"", ""headline"": ""1 Biotech Stock That Could Be the Next Amgen"", ""summary"": ""The emergence of genomic medicine as a viable modality could transform this midcap biotech into the next Amgen.""}, {""date"": ""20231213104030"", ""headline"": ""Big Pharma: Why the drug industry faces a 3-front battle with the FTC, Medicare, and the White House"", ""summary"": ""The Biden administration is increasingly focused on finding ways to lower drug prices, putting the drug industry in a three-way battle to defend its ecosystem.""}, {""date"": ""20231213112603"", ""headline"": ""Amgen Gets FDA Priority Review For Lung Cancer Treatment"", ""summary"": ""By Ben Glickman Amgen has received priority review status from the Food and Drug Administration for its biologics license application for a small cell lung cancer treatment. The Thousand...""}, {""date"": ""20231213113800"", ""headline"": ""Amgen Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Amgen Inc. advanced 2.78% to $281.62 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...""}, {""date"": ""20231213160000"", ""headline"": ""FDA Grants Priority Review to Amgen's Tarlatamab Application for Advanced Small Cell Lung Cancer"", ""summary"": ""Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the Company's Biologics License Application (BLA) for tarlatamab.""}, {""date"": ""20231214000500"", ""headline"": ""Invest with Confidence: Intrinsic Value Unveiled of Amgen Inc"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231214014000"", ""headline"": ""Amgen Reaches Analyst Target Price"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231214030300"", ""headline"": ""Amgen announces senior leadership appointments"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231214043900"", ""headline"": ""Amgen names former Novartis exec James Bradner as chief scientific officer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231214043905"", ""headline"": ""Amgen Names James Bradner Chief Scientific Officer"", ""summary"": ""By Colin Kellaher Amgen has hired James Bradner as executive vice president of research and development and chief scientific officer of the biotechnology company. Amgen on Thursday said...""}, {""date"": ""20231214050000"", ""headline"": ""AMGEN TO SPONSOR THE IRISH OPEN"", ""summary"": ""Amgen (NASDAQ:AMGN) today announced it will serve as the title sponsor of the Irish Open starting in 2024, following the acquisition of Horizon Therapeutics plc in October 2023. Horizon Therapeutics, a leading Irish company, began sponsoring the tournament in 2022 as part of a multi-year commitment to the Irish community.""}, {""date"": ""20231214055100"", ""headline"": ""Market Whales and Their Recent Bets on AMGN Options"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231214061200"", ""headline"": ""Vertex (VRTX) Soars 13.2%: Is Further Upside Left in the Stock?"", ""summary"": ""Vertex (VRTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.""}, {""date"": ""20231214063600"", ""headline"": ""AbbVie, Amgen among firms targeted for latest Medicare inflation penalties"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231214072524"", ""headline"": ""Biopharmaceutical Stocks: The Rally Has Just Begun"", ""summary"": ""With the recent rise in the XBI ETF, investors may begin to wonder if they 'missed the rally'. Read more to see my analysis.""}, {""date"": ""20231214073200"", ""headline"": ""Oppenheimer, Wedbush say buy these biotech stocks for 2024"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231214082400"", ""headline"": ""Amgen's (AMGN) Tarlatamab BLA Gets FDA Priority Tag for SCLC"", ""summary"": ""Amgen's (AMGN) BLA for tarlatamab to treat advanced small cell lung cancer gets FDA's priority review. A decision is expected on Jun 12, 2024.""}, {""date"": ""20231214090000"", ""headline"": ""AMGEN ANNOUNCES EXECUTIVE APPOINTMENTS TO ACCELERATE INNOVATION"", ""summary"": ""Amgen (NASDAQ:AMGN) today announced two changes to its senior leadership team in the areas of research and development (R&D) and technology, underscoring the advancement of the company's robust pipeline and its commitment to ongoing scientific and technological innovation. James Bradner, M.D., has joined Amgen as executive vice president of Research and Development, and chief scientific officer. Bradner is succeeding David M. Reese, M.D., who has been appointed executive vice president and chief""}, {""date"": ""20231214113800"", ""headline"": ""Amgen Inc. stock falls Thursday, underperforms market"", ""summary"": ""Shares of Amgen Inc. slid 1.88% to $276.32 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...""}, {""date"": ""20231215012400"", ""headline"": ""Amgen finds a new top scientist in Novartis veteran Bradner"", ""summary"": ""Jay Bradner, a well-known physician-scientist who left Novartis last year amid an organizational shakeup, will now serve a Amgen\u2019s chief scientific officer and head of R&D.""}, {""date"": ""20231215013000"", ""headline"": ""Dividend Roundup: Alibaba, Amgen, AT&T, Southwest Airlines, and more"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231215032200"", ""headline"": ""Morning Brew: Costco Rises on Strong Sales, Semiconductor Bill Approved"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231215054000"", ""headline"": ""SCHD: Avoid Disaster To Sleep Well At Night"", ""summary"": ""The Schwab U.S. Dividend Equity ETF is surprisingly controversial among the community. Learn why I believe SCHD is a seemingly low-risk ETF.""}, {""date"": ""20231215080016"", ""headline"": ""Amgen Insiders Sold US$5.8m Of Shares Suggesting Hesitancy"", ""summary"": ""In the last year, many Amgen Inc. ( NASDAQ:AMGN ) insiders sold a substantial stake in the company which may have...""}, {""date"": ""20231215113800"", ""headline"": ""Amgen Inc. stock outperforms competitors despite losses on the day"", ""summary"": ""Shares of Amgen Inc. slipped 0.31% to $275.45 Friday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...""}, {""date"": ""20231216223123"", ""headline"": ""Dividend Champion, Contender, And Challenger Highlights: Week Of December 17"", ""summary"": ""Weekly summary of dividend activity for Dividend Champions, Contenders, Challengers. Read more to see the companies with upcoming ex-dividend dates.""}, {""date"": ""20231217090000"", ""headline"": ""Is Amgen Stock a Buy Now?"", ""summary"": ""Boring businesses can be successful, too.""}]",{}
49,2023-12-17,269.50933837890625,2023-12-24,278.03143310546875,0.031620777141982304,U4,"[{""date"": ""20231216223123"", ""headline"": ""Dividend Champion, Contender, And Challenger Highlights: Week Of December 17"", ""summary"": ""Weekly summary of dividend activity for Dividend Champions, Contenders, Challengers. Read more to see the companies with upcoming ex-dividend dates.""}, {""date"": ""20231217090000"", ""headline"": ""Is Amgen Stock a Buy Now?"", ""summary"": ""Boring businesses can be successful, too.""}, {""date"": ""20231217204300"", ""headline"": ""Healthcare Sector Stocks: Consistent Above-Average Growth And Income"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231218061108"", ""headline"": ""XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector"", ""summary"": ""XLV comprises major healthcare industry players and offers a convenient and cost-effective way to invest in the sector. Find out my analysis of XLV ETF.""}, {""date"": ""20231218113900"", ""headline"": ""Amgen Inc. stock rises Monday, still underperforms market"", ""summary"": ""Shares of Amgen Inc. inched 0.01% higher to $275.48 Monday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500...""}, {""date"": ""20231218133500"", ""headline"": ""7 Dividend Stocks to Buy as Bond Yields Fall"", ""summary"": ""Stocks that pay growing dividends are starting look more attractive as bond yields have dropped.  The rate of inflation has continued to decline, and the Federal Reserve is now more likely to cut short-term interest rates than lift them.  Fatter yields from stock dividends now beckon.""}, {""date"": ""20231218170304"", ""headline"": ""Amgen: Bet On Its Breakthrough Drug"", ""summary"": ""Amgen may be impacted by the Inflation Reduction Act and the potential benefits of FDA granting priority review. See why we believe AMGN stock is a buy.""}, {""date"": ""20231218175020"", ""headline"": ""Amgen (AMGN) Advances But Underperforms Market: Key Facts"", ""summary"": ""Amgen (AMGN) reachead $275.48 at the closing of the latest trading day, reflecting a +0.01% change compared to its last close.""}, {""date"": ""20231218204900"", ""headline"": ""Amgen Provides Exposure To Obesity Drug At A Reasonable Price, Says Bullish Analyst"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231218222000"", ""headline"": ""What You Missed On Wall Street On Tuesday"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231218230800"", ""headline"": ""Amgen upgraded to Outperform from Market Perform at BMO Capital"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231219010758"", ""headline"": ""Amgen raised to Outperform on 'promising pipeline': 4 big analyst picks"", ""summary"": ""Here is your Pro Recap of the biggest analyst picks you may have missed today: upgrades at Amgen, Sunrun, American International Group, and Rockwell Automation.  BMO Capital upgraded Amgen (NASDAQ:AMGN) to Outperform from Market Perform and raised its price target to $326.00 from $286.00.  The analysts noted that the upgrade is based on several key factors:Amgen's emerging oral and injectable metabolic pipeline presents an attractive investment opportunity in the obesity metabolic market without the same premium as peers; The completion of the Horizon deal is seen as a strategic move to offset revenues lost to base business erosion; Amgen's promising pipeline, with numerous potential catalysts through 2024, is expected to foster further expansion of its multiple.""}, {""date"": ""20231219012800"", ""headline"": ""Viridian Therapeutics price target raised to $36 from $35 at Oppenheimer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231219013500"", ""headline"": ""Uber To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Tuesday"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231219021700"", ""headline"": ""GLOBAL BROKER RATINGS: Adobe raised to 'overweight'; SAP cut to 'hold'"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231219022600"", ""headline"": ""4 Sizzling Stocks Highlight Tuesday\u2019s Top Wall Street Upgrades and Downgrades"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231219030300"", ""headline"": ""Amgen upgraded by BMO on underappreciated opportunity in obesity/metabolic space"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231219031000"", ""headline"": ""Amgen: Wonderful Stock At Decent Price"", ""summary"": ""Amgen has outperformed S&P 500 and other peers in terms of total returns over the past decade. Read why I maintain my buy rating on AMGN stock.""}, {""date"": ""20231219040100"", ""headline"": ""Amgen shares rise as analysts see \u2018value obesity play\u2019"", ""summary"": ""Shares of Amgen Inc. gained 1.1% premarket on Tuesday after BMO Capital Markets analysts upgraded the stock to outperform, from market perform, citing the...""}, {""date"": ""20231219060400"", ""headline"": ""Dow's nearly 200-point rally highlighted by gains for Walgreens Boots, Amgen stocks"", ""summary"": ""Shares of Walgreens Boots and Amgen are posting positive gains Tuesday morning, lifting the Dow Jones Industrial Average into positive territory. The Dow was...""}, {""date"": ""20231219063400"", ""headline"": ""What You Missed On Wall Street This Morning"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231219070022"", ""headline"": ""Amgen Inc. (NASDAQ:AMGN) is largely controlled by institutional shareholders who own 78% of the company"", ""summary"": ""Key Insights Given the large stake in the stock by institutions, Amgen's stock price might be vulnerable to their...""}, {""date"": ""20231219070600"", ""headline"": ""In-Depth Examination Of 18 Analyst Recommendations For Amgen"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231219094341"", ""headline"": ""Amgen upgraded, PepsiCo downgraded: Wall Street's top analyst calls"", ""summary"": ""Amgen upgraded, PepsiCo downgraded: Wall Street's top analyst calls""}, {""date"": ""20231219113900"", ""headline"": ""Amgen Inc. stock rises Tuesday, outperforms market"", ""summary"": ""Shares of Amgen Inc. rallied 1.07% to $278.44 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20231219141301"", ""headline"": ""BMO Capital Upgrades Amgen (AMGN)"", ""summary"": """"}, {""date"": ""20231219173701"", ""headline"": ""Tracking John Paulson's Paulson & Company Portfolio - Q3 2023 Update"", ""summary"": ""John Paulson's 13F portfolio surged to $1.12B with notable holdings in HZNP, BHC, and more, while making strategic adjustments. Explore more here.""}, {""date"": ""20231219175443"", ""headline"": ""US STOCKS-Wall Street ends higher as rate-cut fever lingers"", ""summary"": ""Wall Street extended its rally on Tuesday, advancing on the day as last week's dovish policy pivot from the Federal Reserve continued to reverberate and investors looked ahead to crucial inflation data.  Broad-based gains boosted all three major U.S. stock indexes and nudged the S&P 500 to within 1 percentage point of its all-time closing high reached in January 2022.""}, {""date"": ""20231219200400"", ""headline"": ""Looking Into Amgen's Recent Short Interest"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231219214100"", ""headline"": ""Noteworthy Wednesday Option Activity: AMGN, ADSK, WSO"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231220034400"", ""headline"": ""CRSP Stock Alert: CRISPR Therapeutics Is Losing Its Medical Chief"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231220113800"", ""headline"": ""Amgen Inc. stock outperforms competitors despite losses on the day"", ""summary"": ""Shares of Amgen Inc. slid 1.17% to $275.18 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20231220200300"", ""headline"": ""CRISPR chief medical officer resigns, stepping down Jan. 26"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231220203400"", ""headline"": ""Spotlight on Amgen: Analyzing the Surge in Options Activity"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231220235800"", ""headline"": ""Daiwa gets more bullish on Amgen, upgrades shares"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231221041200"", ""headline"": ""Blue Chip Sell-Off Stocks Highlight Thursday\u2019s Top Wall Street Upgrades and Downgrades"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231221080516"", ""headline"": ""5 Biotech Acquisition Targets To Accumulate In 2024"", ""summary"": ""Discover why the current slump in biotech valuations presents a great opportunity for acquisitions. Click here to read what investors need to know.""}, {""date"": ""20231221112317"", ""headline"": ""3 Biotech Stocks to Buy in the TradeSmith \u2018Green Zone\u2019"", ""summary"": ""Investors in search of high-risk, high-reward investments can often find them among the top biotech stocks to buy. Identifying worthwhile opportunities can be easier said than done when investing in biotech. Extensive due diligence is required. Therefore you may want to consider taking into account whether a particular biotech stock is in the \u201cGreen Zone.\u201d TradeSmith offers investors valuable tools for determining which stocks to watch. A good example is its Health Indicator feature. This compre""}, {""date"": ""20231221113800"", ""headline"": ""Amgen Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Amgen Inc. rose 1.51% to $279.33 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20231222021206"", ""headline"": ""The Inflation Reduction Act's First Potential Impact On Biosimilars"", ""summary"": ""On October 31, 2023, FDA approved Amgen's Wezlana as a biosimilar to and interchangeable with Janssen's Stelara . Stelara has been selected by the Center for Medicare & Medicaid Services as one of...""}, {""date"": ""20231222044800"", ""headline"": ""Walgreens Boots, Amgen share gains contribute to Dow's 100-point jump"", ""summary"": ""Shares of Walgreens Boots and Amgen are trading higher Friday morning, sending the Dow Jones Industrial Average into positive territory. The Dow is trading...""}, {""date"": ""20231222053600"", ""headline"": ""Biotech stocks set for a rebound in 2024, analysts say"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231222063602"", ""headline"": ""For Those Investors Stuck On Yield, 2023 Was Opportunistic"", ""summary"": ""Discover the power of active stock picking and contrarian investing in today's volatile market. Click here to read what investors need to know.""}, {""date"": ""20231222090006"", ""headline"": ""Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know"", ""summary"": ""Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.""}, {""date"": ""20231222113800"", ""headline"": ""Amgen Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Shares of Amgen Inc. advanced 1.73% to $284.16 Friday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20231222231853"", ""headline"": ""AbbVie Vs. GSK: Dual Dominance In Pharma"", ""summary"": ""AbbVie and GSK are both solid investment choices in the biopharmaceutical industry. Explore more details here.""}, {""date"": ""20231222232425"", ""headline"": ""Bristol Myers Squibb: Aggressive M&A, A Riskier Strategy To Fix The Growth Challenge"", ""summary"": ""Bristol Myers Squibb's (BMY) 2023 outlook is tough, with stagnation and a decline in sales expected, along with increasing debt. Click here to read more.""}, {""date"": ""20231223070300"", ""headline"": ""SCHD: Dividend ETF That Delivers Consistent Dividend Growth"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
50,2023-12-24,278.03143310546875,2023-12-31,281.80816650390625,0.01358383602980906,U2,"[{""date"": ""20231225050302"", ""headline"": ""Capital Gain/Loss On Holdings And Trading Gain/Loss With Cash Cows"", ""summary"": ""I highlight the importance of trade income, capital gains, dividend collection, and tax harvesting in my investment approach. Read more here.""}, {""date"": ""20231225050400"", ""headline"": ""Analyzing Amgen In Comparison To Competitors In Biotechnology Industry"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231226032800"", ""headline"": ""Amgen says FDA has issued new postmarketing requirement for Lumakras"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231226033300"", ""headline"": ""Amgen says FDA declined full approval for lung cancer drug Lumakras"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231226040328"", ""headline"": ""US FDA turns down Amgen lung cancer drug Lumakras for full approval"", ""summary"": ""The U.S. Food and Drug Administrationon Tuesday declined to grant traditional approval to Amgen'sLumakras for treating lung cancer patients with aspecific gene mutation, but did not withdraw the...""}, {""date"": ""20231226042600"", ""headline"": ""Amgen\u2019s NDA for Lumakras cancer treatment resulted in complete response letter"", ""summary"": ""Amgen Inc. said Tuesday that the regulatory review of its supplemental new drug application seeking full approval of Lumakras resulted in a \u201ccomplete...""}, {""date"": ""20231226042900"", ""headline"": ""Video: Dow Movers: AMGN, INTC"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231226044900"", ""headline"": ""Full Approval For Amgen's Flagship Cancer Drug Lumakras Pushed For Around Four Years"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231226090000"", ""headline"": ""AMGEN PROVIDES REGULATORY UPDATE ON STATUS OF LUMAKRAS\u00ae (SOTORASIB)"", ""summary"": ""Amgen (NASDAQ:AMGN) announced today that the U.S. Food and Drug Administration (FDA) has completed its review of the company's supplemental New Drug Application seeking full approval of LUMAKRAS\u00ae (sotorasib). This review, which resulted in a Complete Response Letter, was based on the CodeBreaK 200 trial results for the treatment of adults with previously treated locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer (NSCLC). The FDA also issued a new postmarketing requiremen""}, {""date"": ""20231226090959"", ""headline"": ""UPDATE 2-US FDA turns down full approval of Amgen lung cancer drug Lumakras"", ""summary"": ""The U.S. health regulator on Tuesday declined to grant traditional approval to Amgen's Lumakras for treating lung cancer patients with a specific gene mutation, although it kept the drug's existing accelerated approval status.  The U.S. Food and Drug Administration (FDA) now requires data from an additional confirmatory study to support the drug's full approval, which will be completed no later than February 2028, the company said.  Lumakras was approved by the FDA in 2021 under an accelerated pathway, with confirmatory data as a condition for gaining traditional approval.""}, {""date"": ""20231226113800"", ""headline"": ""Amgen Inc. stock underperforms Tuesday when compared to competitors"", ""summary"": ""Shares of Amgen Inc. dropped 0.09% to $283.90 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...""}, {""date"": ""20231226114729"", ""headline"": ""Midday Movers: Intel's Israel Deal, Bristol-Myers Squibb Buys RayzeBio"", ""summary"": ""U.S. equities continued their pre-Christmas rally into the last week of 2023, with the Dow, S&P 500, and Nasdaq all up.""}, {""date"": ""20231226130553"", ""headline"": ""FDA Wants Another Amgen Study on Lumakras"", ""summary"": ""Amgen will need to run another confirmatory study to win full FDA approval of its lung-cancer drug Lumakras.  Amgen says the FDA, which granted conditional approval to the drug in 2021, has turned away its application seeking full approval and called on the company to complete the additional study by February 2028.  An FDA advisory panel in October raised issues with Amgen's previous confirmatory study, citing problems with how the study was conducted, its small size and relatively minor extension of the time that patients lived without their cancers getting worse.""}, {""date"": ""20231226220000"", ""headline"": ""Healthcare Stocks Had a Terrible 2023. Things Are Looking Up."", ""summary"": ""Things could hardly have gone worse for healthcare investors this year.""}, {""date"": ""20231226223300"", ""headline"": ""Amgen complete response letter has minimal impact, says Barclays"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231227025100"", ""headline"": ""Amgen bid for Lumakras full approval rejected by US FDA"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231227043800"", ""headline"": ""LegoChem signs antibody deal with Amgen worth up to $1.25B"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231227110900"", ""headline"": ""FDA Rejects Amgen's (AMGN) NDA Seeking Full Nod for Lumakras"", ""summary"": ""Per the FDA, Amgen (AMGN) will need to complete an additional confirmatory study on Lumakras in certain lung cancer patients before February 2028 to secure full approval.""}, {""date"": ""20231227113800"", ""headline"": ""Amgen Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Shares of Amgen Inc. inched 0.93% higher to $286.53 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P...""}, {""date"": ""20231227140020"", ""headline"": ""TScan: Two 2024 TCR-T Data Readouts Could Bring Significant Value"", ""summary"": ""TScan's results from T-Plex targeting patients with solid tumors in the Phase 1 study are expected to be released in 2024. Read my analysis of TCRX stock.""}, {""date"": ""20231227180019"", ""headline"": ""Amgen (AMGN) Surpasses Market Returns: Some Facts Worth Knowing"", ""summary"": ""In the latest trading session, Amgen (AMGN) closed at $286.53, marking a +0.93% move from the previous day.""}, {""date"": ""20231227211000"", ""headline"": ""Pharma and biotech deal values spike 35% in 2023: report"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231227220000"", ""headline"": ""Buy AstraZeneca Stock. It Looks Much Better Going Into 2024."", ""summary"": ""The Big Pharma mainstay is set to deliver double-digit earnings growth, driven by a diverse portfolio of blockbusters and promising newcomers.""}, {""date"": ""20231228064700"", ""headline"": ""Amgen's Options: A Look at What the Big Money is Thinking"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231228083900"", ""headline"": ""Biotech Stock Roundup: BMY's KRTX and RYZB Acquisition, CYTK Surges on Study Data"", ""summary"": ""Bristol Myers (BMY) and Cytokinetics (CYTK) are in the news on acquisition announcements and study updates, respectively.""}, {""date"": ""20231228110700"", ""headline"": ""Coherus (CHRS) Stock Rallies on FDA Nod for Udenyca Onbody"", ""summary"": ""The FDA approves Coherus' (CHRS) Udenyca Onbody, an on-body injector presentation of Udenyca (pegfilgrastim-cbqv). Shares of the company rise on the news.""}, {""date"": ""20231228113800"", ""headline"": ""Amgen Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Amgen Inc. inched 0.67% higher to $288.46 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P 500...""}, {""date"": ""20231229000200"", ""headline"": ""Amgen Inc: An Exploration into Its Intrinsic Value"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231229060053"", ""headline"": ""Is Amgen Inc. (NASDAQ:AMGN) Trading At A 40% Discount?"", ""summary"": ""Key Insights Using the 2 Stage Free Cash Flow to Equity, Amgen fair value estimate is US$479 Amgen's US$288 share price...""}, {""date"": ""20231229062328"", ""headline"": ""Viridian Therapeutics: Disconnect Between Fundamentals And Share Price In 2023"", ""summary"": ""Shares of Viridian Therapeutics performed poorly this year, even if we consider the underperformance of biotech stocks. Read more about VRDN stock here.""}, {""date"": ""20231229092400"", ""headline"": ""Can Amgen's Price Strength Continue Into 2024?"", ""summary"": ""Biotechnology firm Amgen  has moved higher on the charts the past seven months and made a new 52-week high on Thursday.  Can this price strength continue or are we looking at a \""last gasp\"" as we head into the new year?  Prices are trading above the 50-day moving average line but the slope of the line is neutral or flat.""}, {""date"": ""20231229113800"", ""headline"": ""Amgen Inc. stock falls Friday, still outperforms market"", ""summary"": ""Shares of Amgen Inc. sank 0.15% to $288.02 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20231229172154"", ""headline"": ""Neurological and obesity drugs will be prevalent in 2024"", ""summary"": ""The rollout of GLP-1 weight loss drugs was prevalent in several pharmaceutical companies' 2023 narratives, among other core biotech products. Jefferies Managing Director Michael Yee joins Yahoo Finance Live to discuss the outlook for pharma and biotech companies in 2024, predicting an increase in M&A activity and continuance of investments into certain drug treatments. \""Obesity is one area, I would definitely say you can't just say it is going to be obesity,\"" Yee says. \""Neurology, Alzheimer's, but more broadly... schizophrenia, depression, Parkinson's, other important areas \u2014 neurology is perhaps one of the biggest epidemics across our country.\"" For more expert insight and the latest market action, click\u00a0here\u00a0to watch this full episode of Yahoo Finance Live.""}, {""date"": ""20231229175020"", ""headline"": ""Amgen (AMGN) Stock Moves -0.15%: What You Should Know"", ""summary"": ""The latest trading day saw Amgen (AMGN) settling at $288.02, representing a -0.15% change from its previous close.""}, {""date"": ""20231231052603"", ""headline"": ""Chevron, Kimberly-Clark Among 14 Companies To Announce Dividend Increases In January"", ""summary"": ""Investors celebrate double-digit increases for Mastercard and Broadcom.""}, {""date"": ""20231231060600"", ""headline"": ""Morgan Stanley positive on healthcare services despite election year"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
